Compositions and methods for treatment of peripheral nerve injury

A composition of agrin, NRG1, and ACh, potentially with a collagen scaffold, addresses the limitations of current RLN injury treatments by promoting neuronal regeneration and reinnervation, achieving restored glottic function and vocal fold symmetry.

WO2026236353A1PCT designated stage Publication Date: 2026-11-12THE TRUSTEES OF INDIANA UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026888
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for vocal fold paralysis due to recurrent laryngeal nerve (RLN) injury, such as temporary medialization with injectables or synthetic material implantation, do not restore normal glottic function and are technically challenging, often resulting in subpar voice outcomes and synkinesis.

Method used

Administration of a composition comprising agrin, neuregulin (NRG1), and acetylcholine (ACh), optionally with a collagen scaffold, to promote neuronal regeneration and reinnervation of the RLN, enhancing neuromuscular junctions and muscle integrity.

Benefits of technology

The composition significantly improves neuronal regeneration, reinnervation, and muscle morphology, leading to restored glottic function and reduced muscle atrophy, with improved vocal fold motion and symmetry.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026888_12112026_PF_FP_ABST
    Figure US2026026888_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed are biomolecules, compositions, and methods for use in treating peripheral nerve, e.g., recurrent laryngeal nerve (RLN) or sciatic nerve injury, including promoting neuronal regeneration and reinnervation after nerve injury. Also disclosed are methods of treating recurrent laryngeal nerve (RLN) injury in a subject comprising administering a composition comprising agrin, neuregulin (NRG1), acetylcholine (ACh), and optionally, a collagen scaffold, and pharmaceutical compositions.
Need to check novelty before this filing date? Find Prior Art

Description

Atty Docket No. 144578.00484 COMPOSITIONS AND METHODS FOR TREATMENT OF PERIPHERAL NERVE INJURY CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims priority to U.S. Provisional Patent Application No.63 / 801,583 that was filed May 7, 2025, the entire contents of which are hereby incorporated by reference.BACKGROUND

[0002] Vocal fold paralysis (VFP) is frequently encountered in otolaryngology practice, negatively impacting patients' quality of life by impairment of phonation and swallowing. Recurrent laryngeal nerve (RLN) damage is one of the most common etiologies of VFP, often resulting from iatrogenic injury, malignancy, and / or trauma. Most surgical interventions for VFP temporarily medialize the paralyzed vocal fold with injectables, or include implantation of synthetic materials through the lary ngeal cartilage framework. These interventions do not offer restoration of normal glottic function (motion). Laryngeal reinnervation to restore vocal fold adduction is an alternative intervention; however, it is technically challenging, not offered by many surgeons, and voice outcomes may be subpar due to synkinesis. The limitations of current VFP management warrant development of a biotherapeutic injectable that medializes the injured vocal fold, promotes lary ngeal reinnervation, and minimizes synkinesis to achieve targeted restoration of glottic function.SUMMARY

[0003] In an aspect of this disclosure, methods of treating peripheral nerve injury7in a subject are provided. In some embodiments, the methods comprise administering a composition comprising agrin, neuregulin (NRG1), and acetylcholine (ACh) to the subject.

[0004] In an aspect of this disclosure, methods of increasing neuronal regeneration and reinnervation after RLN injury in a subject are provided. In some embodiments, the methods comprise administering a composition comprising agrin, NRG1, Ach to the subject to increase neuronal regeneration and reinnervation after RLN injury in the subject.

[0005] In an aspect of this disclosure, pharmaceutical compositions are provided. In some embodiments, the pharmaceutical compositions comprise agrin, neuregulin (NRG1), and acetylcholine (ACh).Atty Docket No. 144578.00484

[0006] In an aspect of this disclosure, methods of treating recurrent laryngeal nerve (RLN) injury in a subject are provided. In some embodiments, the methods comprise administering a composition comprising agrin, neuregulin (NRG1 ), and acetylcholine (ACh) to the subject to treat RLN injury in the subject.BRIEF DESCRIPTION OF THE FIGURES

[0007] FIG. 1: shows an illustration of agrin, acetylcholine, and neuregulin in the mechanism of inducing MPCs to become MEEs with release of neurotrophic and angiogenic factors. Agrin acts through the lipoprotein receptor-related protein 4 (Lrp4) and muscle-specific receptor tyrosine kinase (MuSK) to promote clustering and stabilization of acetylcholine receptors (AChRs).39'48Neuregulin 1 acts via ErbB receptors to induce MuSK phosphorylation, leading to elevated AChR expression and stabilization of the motor endplate.49'32Finally, with AChRs being activity dependent, the presence of ACh binds the clustering receptors for activation and stabilization.37

[0008] FIG. 2 shows an overview of project indicating the timing of survival surgeries, laryngeal testing, and tissue harvesting on days Day 0, 7, and 28 after injection of saline, cocktail, and G+C treatment groups. Asterisk refers to the treatment groups outlined under the Day 0 description and includes: saline, cocktail, and G+C. An additional 4 mice were used at 7- and 28- day time points as normal controls that did not undergo transection as shown in image above.

[0009] FIG.3 shows video laryngoscopy time points of bilateral vocal folds after 28 days of their respective treatment in each row. Figures are labeled as the following groups: (A-B) - Normal, non-transected group, (C+D) - Saline 28-day, (E+F) - Cocktail 28-day, (G-H) - Gelatin + Cocktail. The first image of each row displays the vocal fold positioning at full abduction with the second image representing glottic closure. All treatment groups underwent right RLN transection and had an immobile right vocal. The normal mouse did not undergo transection and had a fully mobile right vocal fold.

[0010] FIGs. 4A, 4B, and 4C FIG. 4A shows electromyography data after stimulation with 5 mAMP stimulation of the right RLN. The asterisk on graph A is referring to the normalization of the right area-under-the-curve (AUC) to the left for each mouse. FIG. 4B shows statistically significant differences between the 28-Day treatment groups for the right AUC after 5 mAMP stimulation of right thyroarytenoid muscle. FIG. 4C shows isolation of the right RLN prior to transection during the survival surgery' compared to the right image of regenerated nerve fibrous band after 28-day treatment with G+C.Atty Docket No. 144578.00484

[0011] FIG. 5 shows image displays NFL (455nm, green) / SV2 (555nm, red) / CHRNAl(647nm, yellow) combined immunofluorescent staining at 400X on the Leica DM2500 microscope to represent nerve regeneration after respective treatments at 7- or 28- days. D APT (blue) counterstain was used to indicate myofiber nuclei. For each time point, the first row represents the combined NFL / SV2 / CHRNA1 assay to show the presence of new NMJs within the selected myofibers. The second row displays only NFL / SV2 to highlight nerve markers signifying nerve presence.

[0012] FIG. 6 shows combined NFL / SV2 / CHRNA1 staining from a G+C, 28-Day mouse at 200X magnification to highlight individual motor end plates (MEPs) at NMJs. FIG. 6A is CHRNA1 only with the DAPI counterstain to highlight the presence of MEP 1, MEP 2, and MEP 3 on the respective myofibers. FIG. 6B highlights SV2 / NFL only with the DAPI counterstain to highlight neuronal regeneration. SV2 staining represents pre-synaptic vesicles and can be seen adjacent to their associated MEPs from Image A. NFL indicates neuronal presence overall. FIG.6C is the combined NFL / SV2 / CHRNA1 stain with all components of the NMJ visible.

[0013] FIG. 7 shows desmin (488nm, green) / Murfl (555nm, orange) combined immunofluorescent staining at 100X to represent muscle integrity after 7- or 28- days with their respective treatments. DAPI (blue) counterstain was used to indicate myofiber nuclei. For each time point, the first row represents the Desmin only assay to confirm presence the thyroarytenoid muscle. The second-row displays Murfl, a measure of muscle atrophy,53to highlight muscle atrophy in the respective muscle.

[0014] FIGs.8A and 8B: FIG. 8 A shows mean myofiber diameters for each treatment group with standard errors. FIG. 8B shows qPCR fold change for each treatment group for Nos 3. Ntf5, Chrnal, and Bdnfio represent RNA expression of vascular and nerve regenerative genes. All 7-day fold change values were compared to the saline 7- day fold change and all 28-day time points were compared to the saline 28- day fold change. The low Chmal levels in the Cocktail 7 Day group followed by an increase in CHRNA1 at 28 days may have occurred due an initial high-dose inhibitory transcriptional effect, which resolved over time as the biomolecule concentration declined into therapeutic values. The Gelatin+Cocktail groups likely facilitated lower but more consistent biomolecule release over time, maintaining elevated CHRNA1 expression. *Refers to no amplification. **One technical replicate within sample did not amplify.

[0015] FIG.9 shows project overview demonstrating experimental timelines for RLN and sciatic nerve injury models. Animals underwent nerve transection and treatment follow ed by longitudinal functional and histologic assessment to evaluate neuromuscular regeneration and reinnervation.Atty Docket No. 144578.00484

[0016] FIGs. 10A, 10B, IOC, 10D, 10E, and 10F show Videolaryngoscopy assessment of bilateral vocal fold motion at 84 days following treatment. Images demonstrate adduction (left) and full abduction (right) of the vocal cords across groups: (A,B) normal uninjured; (C,D) saline-treated; and (E,F) biomolecule-treated. All treatment groups underwent right RLN transection and exhibited immediate postoperative immobility of the right vocal fold. In normal animals, the right vocal fold demonstrates smooth, symmetric abduction relative to the left, whereas saline-treated animals exhibit minimal right vocal fold movement. Biomolecule-treated animals show partial restoration of right vocal fold motion, with improved but incomplete symmetry compared to the contralateral side.

[0017] FIGs. 11A, 11B, and 11C show: RLN EMG symmetry and gross nerve appearance at 84 days following transection. (A) Comparison of right (injured) versus left (uninjured) stimulated RLN EMG activity at 84 days following transection, expressed as the difference in AUC between the right and left sides to assess bilateral symmetry. Small points represent individual animals, while large points indicate group means with lines denoting 95% confidence intervals. The dashed vertical line represents perfect symmetry between right and left EMG activity. Biomolecule-treated animals did not demonstrate significant asymmetry between the right and left sides, while saline exhibited persistent asymmetry, indicating restoration of bilateral symmetry with biomolecule treatment. (B) Representative gross image of the intact RLN in a normal uninjured mouse. (C) Representative gross image of the regenerated RLN 84 days following biomolecule treatment.

[0018] FIGs. 12 shows sciatic nerve EMG symmetry at 28 and 84 days following transection. Comparison of left (injured) versus right (uninjured) stimulated sciatic nerve EMG activity, expressed as the difference in AUC between sides to assess bilateral symmetry'. Small points represent individual animals, while large points indicate group means with lines denoting 95% confidence intervals. The dashed vertical line represents perfect symmetry between left and right EMG activity. Top panel: 28 days; bottom panel: 84 days. Persistent asymmetry was observed across saline and biomolecule-treated groups at both timepoints, indicating no restoration of electrical symmetry' following sciatic nerve injury.

[0019] FIG. 13 shows longitudinal functional recovery assessed by Bioseb kinetic weightbearing (force curve area ratio, rear left / right). A ratio of 1.0 represents perfect symmetry between injured (left) and uninjured (right) hindlimbs, as indicated by7the dashed horizontal line. Data are presented as group means with standard error of the mean across time points following injury, with an axis break between 28 and 84 days. Sample sizes reflect separate timepoint groups, with n = 10Atty Docket No. 144578.00484 through 28 days and n = 5 at all later timepoints. Asterisks indicate values not significantly different from 1.0 (p > 0.05, one-sample t-test). Biomolecule-treated animals demonstrated a nonsignificant trend toward improved symmetry at early timepoints but remained persistently asymmetric, similar to saline-treated animals, through 84 days.

[0020] FIGs. 14A, 14B, 14C, 14D, 14E, 14F, and 14G show immunohistochemical assessment of neuromuscular junction reinnervation following RLN injury. (A-D) Representative CHRNA1 (647 nm, yellow), NF-L (455 nm, green), and SV2 (555 nm, red) staining of the TA muscle at 84 days following RLN transection at 400x on the Leica DM2500 microscope to represent nerve regeneration after biomolecule treatment. (A) CHRNA1 staining highlights nicotinic acetylcholine receptors localized to motor end plates. (B) NF-L staining demonstrates neuronal structures within the TA muscle. (C) SV2 staining indicates postsynaptic vesicle localization adjacent to motor end plates. (D) Merged image of CHRNA1, NF-L, SV2, and DAPI demonstrating the spatial relationship of motor endplates, postsynaptic terminals, and neuronal elements. Arrows highlight representative sites of neuromuscular junction reinnervation. (E-G) Representative merged immunofluorescence images (CHRNA1, NF-L, SV2, DAPI) at 200x of right (injured) TA muscle from (E) normal uninjured mice, (F) saline-treated mice, and (G) biomolecule-treated mice at 84 days. Compared to saline, biomolecule-treated muscle demonstrates increased colocalization of motor endplates with neuronal and synaptic markers, consistent with enhanced neuromuscular junction reinnervation.

[0021] FIGs. 15A, 15B, 15C, 15D, 15E, 15F, and 15G show sciatic nerve regeneration and neuronal staining following treatment. (A) Representative gross image of regenerated sciatic nerve tissue in the biomolecule-treated group at harvest, demonstrating a continuous nerve band at the site of prior transection. (B-D) Neurofilament light chain (NF-L) staining of nerve tissue sections (gastrocnemius and sciatic nerve) at 28 days taken at 200x on the Leica DM2500 microscope from (B) normal uninjured mice, (C) saline-treated mice, and (D) biomolecule-treated mice. (E-G) NF-L staining of corresponding nerve tissue sections at 84 days from (E) normal uninjured mice, (F) saline-treated mice, and (G) biomolecule-treated mice. Immunopositivity (brown) indicates the presence of neuronal structures. Biomolecule-treated samples demonstrated greater NF-L positive staining than saline but less than normal at 28 days, with increased staining at 84 days. Saline-treated animals showed minimal to no staining at either timepoint. These findings are consistent with enhanced axonal regeneration in biomolecule-treated animals.Atty Docket No. 144578.00484

[0022] FIG. 16 shows myofiber diameter ratio of the TA muscle at 84 days following RLN transection. Myofiber diameter is expressed as the ratio of right (injured) to left (uninjured) muscle, with the dashed line indicating perfect symmetry (1.0). Light points represent individual animals, while the central horizontal line indicates the group mean with 95% confidence intervals. Asterisks denote statistically significant differences between groups (p < 0.05, Games-Howell post hoc). Biomolecule-treated animals demonstrated significantly greater myofiber diameter ratios compared to saline and were not significantly different from normal controls, indicating preservation of myofiber symmetry.

[0023] FIG. 17 shows blinded vidcolaryngoscopy scoring at 84 days following RLN transection. Dot plots display individual animal scores with group means (black bars) for spontaneous vocal fold movement (left), vocal cord position (middle), and right (injured) RLN stimulation-evoked responses (right) across normal, saline, and biomolecule-treated groups. All assessments were performed in a blinded fashion. Biomolecule-treated animals demonstrated significantly improved right RLN stimulation responses compared to saline, with trends toward improvement in spontaneous movement and vocal fold position.

[0024] FIGs. 18A and 18B show myofiber diameter of the gastrocnemius muscle at 28 and 84 days following sciatic nerve transection. (A) Myofiber diameter injury ratio is expressed as the ratio of injured (right) leg to uninjured contralateral (left) leg myofiber diameter, with the dashed line indicating perfect symmetry (1.0). Light points represent individual animals. Asterisks denote statistically significant differences from perfect symmetry (*p <0.05, **p<0.01. one sample t-test). At 28 days, both saline and biomolecule-treated animals demonstrated significant asymmetry. At 84 days, the biomolecule group was not significantly different from unity, indicating recovery7toward myofiber symmetry . (B) Example image of myofiber segmentation in ImageJ before size and ratio exclusion criteria are applied to filter for true myofibers.

[0025] FIG. 19 shows an exemplary schematic for the experimental methods in Example 2.

[0026] FIG.20 shows Table 1 : overview of Treatment Groups with Composition of Biomolecular Cocktail Injection. Four treatment groups were created using different concentrations of agrin and NRG. All treatment groups consisted of lOOuM of Ach. Treatment groups consisted of either low-dose or high-dose agrin and NRG.

[0027] FIG. 21 shows intraoperative Image of Uninjured and Regenerated RLN nen e. Figure A shows the intraoperative image during survival surgery of the RLN nerve before transection. Figure B sho s the nerve during initial RLN transection surger . The arrows indicates the distal end ofAtty Docket No. 144578.00484 the transected right RLN . Figure C demonstrates the fibrous band and RLN nerve regeneration seen during harvest surgery 28 days following RLN transection and treatment 2

[0028] FIG. 22 shows EMG Analysis Of Thyroarytenoid 28 Days Following RLN Transection And Treatment. Comparison of Mean AUC (right injured RLN compared to left uninjured) between treatment groups. The height of the bar graph represents the Mean AUC ratio, with the error bar representing one standard deviation above and below the mean for each group. The individual dots correspond to each mouse’s individual Mean AUC within each treatment group. The significant brackets list above the bar graph shows individual groups that were statistically significantly different from each other with their corresponding P values. The table depicts the mean AUC ratio between the injured and treated RLN compared with the uninjured side. A Welch’s ANOVA was used to compare Mean AUC (Right / Left) between treatment groups (p =4.9 xlO'4)

[0029] FIG. 23 shows blinded Videolaryngoscopy Scoring At 28 Days Following RLN Transection. Dot plots display individual animal scores with group medians (black bars) for spontaneous vocal fold movement (A), right (injured) RLN stimulation-evoked responses (B), and VF position at rest (C) across treatment groups. All assessments were performed in a blinded fashion. Individual colored dots represent the score given to each mouse in the representative treatment group. Brackets listed above the dot plot indicate significant differences between groups and the corresponding P values.DETAILED DESCRIPTION

[0030] This disclosure provides biomolecules, compositions, and methods for use in treating recurrent laryngeal nerve (RLN) injury, including promoting neuronal regeneration and reinnervation after RLN injury.Compositions

[0031] The inventors discovered that administration of a composition comprising agrin, neuregulin (NRG1), and acetylcholine (ACh), with or without a collagen scaffold, resulted in a notable increase in innervated neuromuscular junctions (NMJs) in the denervated muscle, with findings similar to the contralateral (uninjured) side at both 7 and 28 days post denervation (FIG.5). The inventors further discovered that the disclosed compositions are effective in regenerating peripheral nerves following injury using both recurrent laryngeal nene (RLN) and sciatic nerve injury models (see, e.g., FIGs. 5 and 15-16).Atty Docket No. 144578.00484

[0032] Accordingly, in one aspect of the disclosure a composition of biomolecules, including one or more of agrin. neuregulin (NRG1), and acetylcholine (ACh) is provided. The composition may be used for, e.g., a method of treating recurrent laryngeal nerve (RLN) injury in a subject.

[0033] The inventors further discovered that, though all animals treated with the combination of agrin, NRG1, and ACh showed a regenerated right RLN band at 28 days, the RLN band in the animals treated with agrin, NRG1, ACh, in a gelatin scaffold had unexpectedly thicker and more prominent bands with increased diameter (FIG. 8A) indicating improved regeneration. Accordingly, the composition may further comprise a collagen scaffold, e.g., a gelatin scaffold.

[0034] Additional collagen scaffolds are known in the art and include, but are not limited to, the collagen scaffolds listed below in Table 2.

[0035] Table 2. Exemplary collagen scaffolds.Category ExamplesCollagen, type I collagen, type III collagen, type I / III collagen Native collagen materials mixtures, fibrillar collagen, reconstituted collagen, soluble collagenAtelocollagen, telocollagen, acid-solubilized collagen, pepsin- Processed collagentreated collagenDenatured or hydrolyzedGelatin, hydrolyzed collagen, collagen peptidescollagen derivativesChemically modified Methaciylated gelatin / GelMA, methacrylated collagen, collagen / gelatin crosslinked collagen, functionalized collagenInjectable collagen gel, collagen hydrogel, collagen sponge, Collagen matrix formats collagen foam, collagen membrane, collagen sheet, collagen film, collagen scaffold, collagen pasteCollagen microspheres, microparticles, nanoparticles, miniParti culate / depot formatspellets, beads, injectable depotsCollagen-gelatin, collagen-hyaluronic acid, collagen-fibrin, Composite collagencollagen-alginate, collagen-chitosan, collagen-PEG, collagencarrierslaminin, collagen-ECM compositesAtty Docket No. 144578.00484 Synthetic collagen-like Collagen-mimetic peptides, collagen-like polypeptides, materials recombinant collagen, synthetic collagen hydrogels

[0036] The gelatin may be, e.g., a sterile porcine gelatin. Suitable gelatins are known in the art.

[0037] In another aspect, a gelatin-infused injectable, or a collagen scaffold, comprising one or more of agrin, neuregulin (NRG1), and acetylcholine (ACh) is provided.

[0038] The compositions / injectables may comprise a concentration of agrin about 50 nM to about 5000 nM, or any subrange or value therein, e.g., about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM, about 100 nM, about 110 nM, about 120 nM, about 130 nM, about 140 nM, about 150 nM, about 160 nM, about 170 nM, about 180 nM, about 190 nM, about 200 nM, about 210 nM, about 220 nM, about 230 nM, about 240 nM. about 250 nM. about 260 nM. about 270 nM, about 280 nM, about 290 nM, about 300 nM, about 310 nM, about 320 nM, about 330 nM, about 340 nM, about 350 nM, about 360 nM, about 370 nM, about 380 nM, about 390 nM, about 400 nM, about 410 nM, about 420 nM, about 430 nM, about 440 nM, about 450 nM, about 460 nM, about 470 nM, about 480 nM, about 490 nM, about 500 nM, about 510 nM, about 520 nM, about 530 nM, about 540 nM, about 550 nM, about 560 nM, about 570 nM, about 580 nM, about 590 nM, about 600 nM, about 610 nM, about 620 nM, about 630 nM, about 640 nM, about 650 nM, about 660 nM, about 670 nM, about 680 nM, about 690 nM, about 700 nM, about 710 nM, about 720 nM, about 730 nM, about 740 nM, about 750 nM, about 760 nM, about 770 nM, about 780 nM, about 790 nM, about 800 nM. about 810 nM. about 820 nM. about 830 nM. about 840 nM, about 850 nM, about 860 nM, about 870 nM, about 880 nM, about 890 nM, about 900 nM, about 910 nM, about 920 nM, about 930 nM, about 940 nM, about 950 nM, about 960 nM, about 970 nM, about 980 nM, about 990 nM, about 1000 nM, about 2000 nM, about 3000 nM, about 4000 nM, about 5000 nM. Agrin may be purchased commercially or produced recombinantly.

[0039] The compositions / injectables may comprise a concentration of NRG1 about 0.1 nM to about 100 nM, or any subrange or value therein, e.g., about 0.1 nM, about 0.2 nM, about 0.3 nM, about 0.4 nM, about 0.5 nM, about 0.6 nM, about 0.7 nM, about 0.8 nM, about 0.9 nM, about 1 nM, about 2 nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM. about 8 nM, about 9 nM, about 10 nM, about 20 nM, about 30 nM, about 40 nM, about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM, about 100 nM. The NRG1 may be human NRG1 and have the sequence SEQ ID NO: 1, or have a sequence with at least about 80%, at least about 81%, at leastAtty Docket No. 144578.00484 about 82%. at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%. at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identity to SEQ ID NO: 1.

[0040] The compositions / injectables may comprise a concentration of ACh about 10 micromolar to about 1000 micromolar, or any subrange or value therein, e.g., about 10 micromolar, about 20 micromolar, about 30 micromolar, about 40 micromolar, about 50 micromolar, about 60 micromolar, about 70 micromolar, about 80 micromolar, about 90 micromolar, about 100 micromolar, about 200 micromolar, about 300 micromolar, about 400 micromolar, about 500 micromolar, about 600 micromolar, about 700 micromolar, about 800 micromolar, about 900 micromolar, about 1000 micromolar. ACh may be purchased commercially.

[0041] In some embodiments, the concentration of agrin is about 500 nM, the concentration of NRG is about 1 nM, and the concentration of ACh is about 100 pM.Methods of treating peripheral nerve injury

[0042] As noted above, the inventors discovered that administering a composition comprising agrin, neuregulin (NRG1), and acetylcholine (ACh) improved reinnervation of the RLN in an animal model of RLN injury and also improved nerve regeneration in a model of sciatic nerve injury. Accordingly, in a further aspect of the disclosure, a method of treating peripheral injury in a subject is provided. The sciatic nerve is the largest peripheral nerve in the body, making it the most difficult to regenerate. Therefore, the surprising regeneration of the sciatic nerve indicates that any peripheral nerve can be regenerated by the disclosed methods.

[0043] In some embodiments, the peripheral nerve is the RLN. In some embodiments, the peripheral nerve is the sciatic nerve. In some embodiments, the methods include administering a composition of the biomolecules agrin, neuregulin (NRG1), and acetylcholine (ACh). The composition may further comprise a gelatin.

[0044] The composition may be administered by any effective route, for example by inj ection. In some aspects, the composition is injected into muscle. In some aspects, the muscle may be laryngeal muscle, or denervated laryngeal muscle. The composition may be administered to the thyroarytenoid (TA) muscle.

[0045] Using an animal model of RLN injury, the inventor discovered that saline (vehicle control) animals showed a significant increase in atrophy based on MuRF-1 immunopositivity on the injured side compared to the contralateral uninjured muscle at 28 days post denervation (FIG. 7,Atty Docket No. 144578.00484 showing desmin (muscle cell marker) in rows 1 and 3 and Murfl (marker of atrophy) in rows 2 and 4, showing increased Murfl staining in “normal7’ and “saline” treated controls compared to both agrin, NRG1, and ACh (“cocktail”) and the “cocktail” in a gelatin scaffold “Gelatin + Cocktail”). In contrast, denervated sides treated with the bioactive molecules agrin, NRG1, and ACh (“cocktail”) and cocktail in a gelatin scaffold (“G+C”) showed notably less atrophy at 7- and 28-day time points compared to the saline controls and demonstrated similar muscle morphology as the uninjured side with similar levels of MuRFl immunopositivity (rows 2 and 4 of FIG. 7). Accordingly, in some aspects, the methods attenuated muscle atrophy in the subject.

[0046] In some aspects, glottic function in the subject is restored.

[0047] The concentrations of biomolecules in the composition and administration of the composition may be as described above.

[0048] The disclosed methods may comprise administering the compositions once, twice, three times, four times, five times, six times, seven times, eight time, nine times, ten times, or more to the subject, as directed by a physician. The methods may comprise administering the compositions according to any particular schedule, e.g., once per week, once per month, once per year, etc., under the direction of a physician.

[0049] The methods may comprise administering the compositions in combination with an additional therapeutic.

[0050] The composition and the additional therapeutic may be administered at the same time, or at different times, in any order.Methods of increasing neuronal regeneration and reinnervation after recurrent laryngeal nerve injury

[0051] As discussed above, the inventors discovered that administering a composition comprising agrin, NRG1 , and ACh, induced neuronal regeneration and reinnervation in a model of RLN injury. Accordingly, in an aspect of this disclosure, a method of increasing neuronal regeneration and reinnervation after RLN injury in a subject is provided. In some embodiments, the methods comprise administering a composition comprising agrin, NRG1, and ACh. The composition may- further comprise a gelatin. The composition may be administered by any effective route, for example by injection, or on any particular schedule, as discussed above.

[0052] The methods may also attenuate muscle atrophy or restore glottic function in the subject.

[0053] The compositions may be as discussed above.Pharmaceutical compositionsAtty Docket No. 144578.00484

[0054] In an aspect of this disclosure, pharmaceutical compositions are provided. In some embodiments, the pharmaceutical compositions comprise agrin. neuregulin (NRG1), acetylcholine (ACh), and a collagen scaffold, e.g., a gelatin scaffold. The concentrations of the bioactive molecules and collagen scaffold may be as discussed above.

[0055] The pharmaceutical compositions may further comprise a pharmaceutically acceptable carrier, which are known in the art.

[0056] The compounds utilized in the methods disclosed herein may be formulated as a pharmaceutical composition that includes one or more binding agents, fdling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, and effervescent agents. Filling agents may include lactose monohydrate, lactose anhydrous, and various starches; examples of binding agents are various celluloses and crosslinked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel® PHI 01 and Avicel® PH102, microcrystal I me cellulose, and silicified microcrystalline cellulose (ProSolv SMCC™). Suitable lubricants, including agents that act on the flowability of the powder to be compressed, may include colloidal silicon dioxide, such as Aerosil®200. talc, stearic acid, magnesium stearate, calcium stearate, and silica gel. Examples of sweeteners may include any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame. Examples of flavoring agents are Magnasweet® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like. Examples of preservatives may include potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxy benzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quaternary' compounds such as benzalkonium chloride.

[0057] Suitable diluents may include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and mixtures of any of the foregoing. Examples of diluents include microcrystalline cellulose, such as Avicel® PHI 01 and Avicel® PHI 02; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose® DCL21; dibasic calcium phosphate such as Emcompress®; mannitol; starch; sorbitol; sucrose; and glucose.

[0058] Pharmaceutical compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.Atty Docket No. 144578.00484 The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.Miscellaneous definitions

[0059] The present invention is described herein using several definitions, as set forth below and throughout the application.

[0060] As used herein, “effective amount” or “therapeutically effective amount” refers to the amount of the biomolecule, composition, or pharmaceutical composition necessary to improve one sign or symptom of a subject’s disease or disorder, e.g., nerve injury.

[0061] Administration, and grammatical variations thereof, may comprise administration by any appropriate route, e.g., injection, e.g., injection to muscle. Illustrative routes of administration include transdermal, percutaneous, intravenous, intramuscular, intranasal, buccal, and intrathecal routes. The particular dose and administration route may be as described in this disclosure or can be determined by a physician.

[0062] Further definitions

[0063] The disclosed subject matter may be further described using definitions and terminology as follows. The definitions and terminology used herein are for the purpose of describing particular embodiments only and are not intended to be limiting.

[0064] As used in this specification and the claims, the singular forms “a,” “an,” and “the” include plural forms unless the context clearly dictates otherwise. For example, the term “a substituent” should be interpreted to mean “one or more substituents,” unless the context clearly dictates otherwise.

[0065] As used herein, “about”, “approximately,” “substantially,” and “significantly” will be understood by persons of ordinary' skill in the art and will vary' to some extent on the context in which they are used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, “about” and “approximately” will mean up to plus or minus 10% of the particular term and “substantially” and “significantly” will mean more than plus or minus 10% of the particular term.

[0066] As used herein, the terms “include” and “including” have the same meaning as the terms “comprise” and “comprising.” The terms “comprise" and “comprising” should be interpreted asAtty Docket No. 144578.00484 being “open’' transitional terms that permit the inclusion of additional components further to those components recited in the claims. The terms “consist” and “consisting of’ should be interpreted as being “closed” transitional terms that do not permit the inclusion of additional components other than the components recited in the claims. The term “consisting essentially of’ should be interpreted to be partially closed and allowing the inclusion only of additional components that do not fundamentally alter the nature of the claimed subject matter.

[0067] The phrase “such as” should be interpreted as “for example, including.” Moreover, the use of any and all exemplary language, including but not limited to “such as”, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed.

[0068] Furthermore, in those instances where a convention analogous to “at least one of A, B and C, etc.” is used, in general such a construction is intended in the sense of one having ordinary skill in the art would understand the convention (e.g., “a system having at least one of A, B and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A. B, and C together.). It will be further understood by those within the art that virtually any disjunctive word and / or phrase presenting two or more alternative terms, whether in the description or figures, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or B or “A and B . ”

[0069] All language such as “up to,” “at least,” “greater than,” “less than,” and the like, include the number recited and refer to ranges which can subsequently be broken down into ranges and subranges. A range includes each individual member. Thus, for example, a group having 1-3 members refers to groups having 1, 2, or 3 members. Similarly, a group having 6 members refers to groups having 1, 2, 3, 4. or 6 members, and so forth.

[0070] The modal verb “may” refers to the preferred use or selection of one or more options or choices among the several described embodiments or features contained within the same. Where no options or choices are disclosed regarding a particular embodiment or feature contained in the same, the modal verb “may” refers to an affirmative act regarding how to make or use and aspect of a described embodiment or feature contained in the same, or a definitive decision to use a specific skill regarding a described embodiment or feature contained in the same. In this latter context, the modal verb “may” has the same meaning and connotation as the auxiliary verb “can.” Exemplary embodimentsAtty Docket No. 144578.00484 1. A method of treating recurrent laryngeal nerve (RLN) injury in a subject comprising administering a composition comprising agrin, neuregulin (NRG1), acetylcholine (ACh), and gelatin.2. A method of increasing neuronal regeneration and reinnervation after RLN injury' in a subject, comprising administering a composition comprising agrin, NRG1, ACh, and gelatin.3. The method of embodiment 1 or embodiment 2, wherein the composition is administered to the subject via injection, optionally injection into muscle.4. . The method of any one of embodiments 1-3, wherein muscle atrophy in the subject is attenuated.5. The method of any one of embodiments 1-4, wherein glottic function in the subject is restored.EXAMPLES

[0071] The following Examples are illustrative and should not be interpreted to limit the scope of the claimed subject matter.Example 1 - Novel Biomolecule-Infused Gelatin Injectable for Treatment of Recurrent Laryngeal Nerve Injury

[0072] Vocal fold paralysis (VFP) is frequently encountered in otolaryngology practice, negatively impacting patients' quality of life by impairment of phonation and swallowing.1'4Recurrent laryngeal nerve (RLN) damage is one of the most common etiologies of VFP, often resulting from iatrogenic injury’, malignancy, and / or trauma.2'4Most surgical interventions for VFP temporarily medialize the paralyzed vocal fold with injectables,5'8or include or implantation of synthetic materials through the laryngeal cartilage framework.9'10These interventions do not offer restoration of normal glottic function (motion). Laryngeal reinnervation to restore vocal fold adduction is an alternative intervention; however, it is technically challenging, not offered by many surgeons, and voice outcomes may be subpar due to synkinesis.11,12The limitations of current VFP management warrant development of a biotherapeutic injectable that medializes the injured vocal fold, promotes lary ngeal reinnervation, and minimizes synkinesis to achieve targeted restoration of glottic function.

[0073] Recently, implementation of muscle progenitor cells (MPCs) and their derivatives in animal models of VFP have been explored by our laboratory.13'25MPCs are undifferentiated precursor skeletal muscle cells that include peripheral satellite cells and myoblasts.13'15Motor endplate-expressing cells (MEEs) consist of differentiated MPCs that release neurotrophic factors necessary’ for reinnervation.16'25Discovery’ of MEEs as a therapeutic cell type was initially drivenAtty Docket No. 144578.00484 by research on the natural pathophysiology of human neuromuscular junctions (NMJs). Following sudden muscle injury, myofiber endplates lose post-synaptic signals. In response, the myofibers with denervated endplates release a cascade of physiological neurotrophic factors (NFs) to promote axonal sprouting, neuronal regeneration, and the re-establishment of functional NMJs.26'29Exogenously administered MEEs are believed to restore lary ngeal adductor function after RLN injury’ through amplified site-specific NF release [neurotrophic factor-3 (NTF3), neurotrophic factor-4 (NTF4), neurturin (NRTN), nerve growth factor (NGF)] .16-25

[0074] Priming MPCs to differentiate into MEEs through exposure to a biomolecular cocktail of agrin, neuregulin (NRG1), and acetylcholine (ACh) has been thoroughly described16-25and is illustrated in Figure 1. In theory, exogenous injectable administration of these three biomolecules directly into denervated thyroarytenoid (TA) muscle should increase motor endplate expression within the muscle, thereby leading to amplified NF release and selective muscle reinnervation at the injection site. In the current study, we use gelatin as a biomolecule delivery’ system for delayed site-specific release of agrin, NRG1, and ACh with the goal of both augmenting and selectively promoting reinnervation of a paralyzed vocal fold in a rodent model. Gelatin has been shown to be an effective delivery system for otolaryngological applications and has demonstrated regenerative properties with minimal inflammatory’ side effects.30-32This study aims to create a gelatin-infused injectable containing agrin, NRG1 and ACh, and evaluate its impact on reinnervation and attenuation of atrophy in a rodent model of RLN injury’. We hypothesize that injecting the biomolecules (with or without gelatin) into the paralyzed vocal fold will result in 1) increased motor-endplate expression in histopathological analysis, 2) increased NF release on qPCR analysis, 3) enhanced electromyography (EMG)-based reinnervation compared to controls, and 4) attenuated muscle atrophy in biomolecule treatment groups. We further hypothesize that the gelatin-biomolecule infusion will promote sustained site-specific NF release when compared to the biomolecule cocktail alone, due to delayed diffusion of biomolecules at the injection site.Figure 2 outlines the study timeline along with treatment groups.

[0075] Methods

[0076] Injection Preparation

[0077] Injections were prepared and loaded for the following treatment groups: 0.9% saline, cocktail, and gelatin+cocktail (G+C). The cocktail solution was prepared with the following concentrations of biomolecules in prepared sterile saline: 500 nM agrin (Catalog# 6624-AG, R&D, Minneapolis. Minnesota) 1 nM neuregulin (Catalog# 5898-NR, R&D, Minneapolis. Minnesota),Atty Docket No. 144578.00484 lOO iM of acetylcholine chloride (Catalog# 159170070, Thermo Scientific. Fair Lawn, New Jersey). This solution was used directly for the cocktail only group, and 0.1 g / 1 mL of sterile porcine gelatin (Catalog# 9000-70-8, Sigma Aldrich, St. Louis, Missouri) was added to the cocktail for the G+C treatment. To characterize delayed release of agrin from the G+C injectable, transwell enzyme-linked immunosorbent assay (ELISA) was performed. See Supplemental Information for additional information, including methods and results of ELISA.

[0078] Survival Surgery

[0079] A mouse model was selected for these investigations due to its established translational potential.33,34All surgical procedures followed an lACUC-approved protocol (#23150-A4). Day 0 for each mouse was determined based on the date of survival surgery for all groups except the normal groups: day 0 for normal groups was based the date of arrival after a 72-hour acclimation period. On Day 0, C57 / BL6 mice from the cocktail group (N=16), saline groups (N=16), and G+C groups (n=16) underwent survival surgery' in which the right RLN was transected, and vocal fold immobility was confirmed with video laryngoscopy. Injections of 10 pL treatments (saline, cocktail only, G+C) were administered through the thyroid cartilage into the TA muscle. The mice were housed in LARC facility’ (Laboratory Animal Resource Center) at Indiana University Indianapolis following the LARC facility’ protocol for animal handling and public health service policy.

[0080] Laryngeal Testing

[0081] To test whether successful reinnervation and restoration of muscle function occurred in treatment groups, transoral video lary ngoscopy using an Ambu aScope 5 Broncho 2.7 / 1.2 mm single use flexible endoscope (Catalog# 624001000US, Ambu, Columbia, Maryland) was utilized to visualize vocal fold motion, local inflammation, and positioning of the immobile vocal fold (midline versus lateral). Observations of video laryngoscopy findings were recorded at Day 7 and Day 28 and compared to recordings on the day of the survival surgery (Day 0).

[0082] Laryngeal Electromyography (L-EMG)

[0083] In addition to video laryngoscopy, the mice underwent harvest surgery at their respective 7- or 28-day time point. Intraoperatively. muscle action potentials and bilateral stimulation responses (adduction) were recorded from the bilateral TA muscles while a 5.10 mAMP stimulus was applied to the bilateral RLNs. LEMG stimulation was done on the regenerated fibrous nen e band proximal to, distal to, and at the site of injury7. The present study utilized the UltraPro SI 00Atty Docket No. 144578.00484 EMG system (Catalog# 828-060800, Natus, Middleton, Wisconsin). See Supplemental Information for more detail.

[0084] Histology and Immunohistochemistry

[0085] After euthanizing the mice, larynges from each mouse were isolated, stored and fixed with 10% neutral buffered formalin for 24 hours. After fixation, the larynges were placed in HistoGel (Catalog# HG-4000-012, Richard-Allan Scientific, Kalamazoo, Michigan) to maintain tissue structure for processing by the IUI Histology Core. Histology slides were created with 5um axial sections of the larynges. Immunohistochemistry (IHC) assay development on selected control tissues and the antibodies used for IHC are listed in Supplemental Information. Myofiber diameter was measured for each mouse by utilizing Aperio ImageScope Pathology Slide Viewing Software (Leica, Deer Park, Illinois) to identify diameter approximations of myofibers within scanned H&E images.

[0086] qPCR

[0087] RNA was isolated from two, 20 pm curls from tissue of each animal and qPCR analysis was performed to quantify right-sided gene expression in normal, saline, cocktail, and G+C groups at 7- and 28- day time points. Fold change was calculated from AACt analysis using Gapdh as a baseline to represent relative levels of neurotrophic and angiogenic factor expression in comparison to corresponding 7- and 28- day saline control groups. Further details on qPCR procedure are outlined in Supplemental Information.

[0088] Statistical Analysis

[0089] For all quantitative comparisons of means between treatment groups, a Kruskal-Wallis test and One-Way Welch’s Anova were utilized for non-parametric and parametric data, respectively. Parametric versus non-parametric data was determined using the Shapiro-Wilk test.

[0090] Functional outcomes'.

[0091] Mean area under the curve (AUC) data was normalized by dividing the right RLN AUC by the normal left RLN AUC for each mouse to obtain a proportion that was used to analyze relative functionality of the injured nerve. The following treatment groups were compared: all 28-day groups (normal, saline, cocktail, G+C), all 7-day groups (normal, saline, cocktail, G+C), and all groups from 7- and 28-day timepoints combined. A Mann Whitney U test was utilized to compare the right-to-left AUC proportions between independent 7- and 28-day mice within the same treatment group (e.g., 7-day saline versus 28-day saline).

[0092] Video Laryngoscopy.Atty Docket No. 144578.00484

[0093] A Wilcoxon signed rank test was utilized to compare nonparametric, paired data for pretreatment versus post-treatment vocal fold motion, inflammatory signs, and immobile vocal fold positioning. A Chi-square test was used to determine the side of response after 5.10 mAMP EMG stimulation of the bilateral RLNs. Midline versus lateralized positioning of the immobile injured vocal fold was compared between treatment groups through a Chi-square test with post-hoc pairwise comparisons between treatment groups. Differences of recorded myofiber diameters between treatment groups were analyzed through a One-Way Welch’s ANOVA with post-hoc Games-Howell analysis.

[0094] qPCR.

[0095] A One-Way Welch’s ANOVA was performed for parametric data to identify statistically significant differences between treatment groups in their relative expression levels compared to respective saline groups at 7- and 28-days. A Kruskal-Wallis test was performed to analyze 28-day data for NTF5 given that it is the only group that was nonparametric.

[0096] Results

[0097] Video Laryngoscopy

[0098] Blinded analysis of the videos demonstrated absence of inflammatory changes at 7 and 28 days for the cocktail and G+C groups relative to the saline 28-day group (p=0.408). Bilateral RLN stimulation resulted in bilateral response (adduction) in all 8 / 8 cocktail mice and 8 / 8 G+C groups mice at 28 days in contrast to the saline 28-day group which had response in only 2 / 7 mice (p< 001 ). likely representing functional synkinesis.54Specifically, the remaining 5 / 7 saline 28-day mice experienced only left unilateral responses with bilateral stimulation indicating a lack of response from the injured right RLN. All cocktail (7 / 8) and G+C (8 / 8) 28-day mice showed predominantly midline positioning (p<0.002) compared to the saline 28-day mice which had mostly lateralized positioning (5 / 7 mice). Figure 3 displays 28-day video laryngoscopy images from the normal, saline, cocktail, and G+C groups.

[0099] L-EMG and Nerve Regeneration

[0100] L-EMG readings were collected at the time of harvest surgery 7- or 28-days after injection with treatment groups. The one-way ANOVA with post-hoc analysis showed a statistical difference between treatment groups at 28 days (p<0.001). Results from this analysis and significant quantitative mean AUC findings from the EMG stimulation across the injured segment of the RLN are listed in Figure 4; regenerated right RLN fibrous nerve band after 28 days of G+C treatment is also demonstrated. All animals in the 28-day cocktail and G+C groups had a fibrousAtty Docket No. 144578.00484 band present, however, the G+C bands were thicker and more prominent compared to the cocktail groups.

[0101] Histopathological Analysis

[0102] Multiplex NFL NV2 CHRNA1 assay for nerve regeneration:

[0103] Treatment with cocktail and G+C at 7 days and 28 days showed a notable increase in innervated NMJs in the denervated muscle, with findings similar to the contralateral (uninjured) side (Figure 5). Not only was diffuse CHRNA1 immunopositivity observed (demarcating motor endplates), immunopositivity for SV2 was present adjacent to increased CHRNA1 in the myofibers, consistent with innervated NMJs throughout, as show n in Figure 6. NFL, a neuronal marker, was present throughout the muscle with adjacent increases in CHRNA1 and SV2 indicative of nerve and NMJ regeneration at injury site-specific sites. In contrast, the saline 7- and 28- day groups show ed much less SV2 and NFL (neuronal presence) when compared to the normal non-transected mice (Figure 5).

[0104] Multiplex Desmin / MuRFl assay for muscle integrity and atrophy:

[0105] Saline at 7 days showed minimal muscle atrophy compared to the saline 28-day groups which displayed significant atrophy and muscle damage. Specifically, saline 28-day groups showed a significant increase in atrophy based on MuRF-1 immunopositivity on the injured side compared to the contralateral uninjured muscle. Denervated sides treated with cocktail and G+C showed notably less atrophy at 7- and 28-day time points compared to the saline controls and demonstrated similar muscle morphology as the uninjured side with similar levels of MuRFl immunopositivity. Figure 7 shows the comparison of the Desmin / Murfl staining between treatment groups at 7- and 28-day time points. Myofiber diameter was greater in G+C compared to saline groups at 28 days (mean G+C 36.06 um + / - 2.19 versus saline 21.45 + / - 0.47, p=0.024). Additionally, the G+C 28-day group had higher myofiber diameters than the saline 7-day group mean of 20.9 + / - 1.59 (p=0.006). Of note, the cocktail 28-day group had a mean myofiber diameter of 32.1 um but did not yield statistically significant results. Figure 8 displays a table with all the mean myofiber diameters for each treatment group with standard error values.

[0106] Gene Expression Analysis (qPCR)

[0107] qPCR analysis is displayed in Figure 8.

[0108] Chrnal :

[0109] Analysis showed both cocktail groups (7- and 28-day) and G+C 28-day were not significantly changed from the saline control. G+C 7 day had a higher fold change at 2.47Atty Docket No. 144578.00484 compared to saline. There were no significant differences between the 28-day cocktail and G+C, though their mean fold changes were 1.258 and 1.492, respectively.

[0110] Bdnf.

[0111] Analysis of 7-day data showed a lower mean fold change of 0.159 in the G+C group (p=0.010) and near zero in the cocktail 7-day compared to the saline. The cocktail group at 28-days had a notable mean fold change of 3 however had a p value of 0.305. Comparing 28-day data of Bdnf expression of G+C to saline, the G+C showed a significantly higher fold change of 6.33 (p=0.040).

[0112] Ntf5

[0113] The G+C 28-day group had a significantly higher fold change of 4.94 in Ntf5 expression compared to the saline 28-day group (p=0.016). Cocktail 28-day and G+C 28-day groups had fold changes of 2.047 + / - 1.75 and 4.938 + / - 0.32, respectively though no statistical differences were noted between these treatments.

[0114] Nos3;

[0115] There was no significant difference noted in (7- and 28-day) treatment groups when comparing Nos3 fold changes, however, the cocktail 28-day group had a fold change of 16.07 with a standard error of 10.49.

[0116] Discussion

[0117] This study aimed to examine macroscopic, microscopic, and functional outcomes of injecting denervated larynges with biomolecule-infused gelatin in C57 / BL6 mice. Evaluation of the findings show that injecting acutely denervated laryngeal muscle with agrin, NRG1, and ACh (with or without gelatin) promotes an increase in nene regeneration, innervated NMJs, and overall muscle integrity.

[0118] Functional Outcomes

[0119] All injected mice maintained a steady weight, appetite, respiratory status, and no signs of adverse reactions to any injectables. Video laryngoscopy recordings after 7- and 28-day treatments exhibited no significant changes in vocal fold movement in all treatment groups, which reflects an expected outcome at this early timepoint. Specifically, video laryngoscopy findings in Figure 3 and statistical differences of the injured, immobile vocal fold positioning between the negative control saline group and G+C group supports synkinesis mechanisms. Lateralized vocal fold positioning of the negative control saline group can be explained by disorganized reinnervation of abductor and adductor muscles possibly leading to a slightly abducted position. In contrast, theAtty Docket No. 144578.00484 midline positioning in the G+C group may be explained by targeted reinnervation mechanisms from the biomolecules leading to stronger innervation of the adductor muscles innervated by the RLN.35,36

[0120] Biomolecules Promote Reinnervation and Attenuate Atrophy

[0121] L-EMG data demonstrated a significant increase in right AUC of the denervated TA muscle in the G+C group compared to the saline negative control groups after 28 days, signifying regeneration of the injured RLN. Findings are supported by the presence of a fibrous nen e band which led to successful EMG readings as seen in Figure 4. Bilateral adduction upon stimulation seen in many G+C and cocktail injected animals at 28 days also suggests stimulable innervation had formed in those groups, likely because the regenerated nerve allowed for a stronger sitespecific adductor muscle reinnervation and response.

[0122] Immunofluorescent staining examining nerve regeneration and muscle atrophy attenuation showed promising regenerative effects of the cocktail and G+C groups. Immunopositivity for SV2 and NFL was observed adjacent to Chmal indicating innervated NMJs throughout the treated muscle, specifically at Chmal -upregulated sites. Figure 6 displays how the biomolecules not only contributed to formation of new innervated MEPs but also increased SV2 markers indicative of regenerated nerve at sites of significant NFL staining of nerve damage. Other areas demonstrated Chmal without SV2 and NFL, suggesting non-innervated motor endplate expressing regions. Based on our prior MEE injection studies, these motor endplate-expressing regions should result in site-specific neurotrophic factor release.16,17,19In addition, attenuation of muscle atrophy occurred in both the cocktail and G+C groups in which increased NMJ formation was evident promoted muscle integrity and attenuated muscle atrophy.37'38

[0123] Biomolecules promote Gene Expression of Nos3, Chmal, Bdnf and Ntf5. Comparisons of fold change for QPCR data show significant increases in Bdnf. Chmal, Ntf5 starting as early as 7 days with persistent levels of expression at 28 days. Interestingly, the G+C groups resulted in the most consistent, statistically significant increases in fold changes compared to the cocktail groups for Bdnf, Chmal, and Ntf5 expression at 7- and 28-day time points. This data suggests that gelatin as a delivery system of the cocktail may be allowing for sustained release of the biomolecules over a longer period resulting in increased expression of neurotrophic and angiogenic factors.

[0124] Limitations of this study include genetic differences between mice and humans, translational potential of the mouse model, and early analysis timepoints. Additionally, gelatin alone has been shown to have anti-inflammatory and regenerative properties, so adding a gelatinAtty Docket No. 144578.00484 alone control would have strengthened the design.55Despite these shortcomings, the current findings suggest additional investigation with variable time between injury and injection, longer follow-up, and alternative preclinical models is warranted.

[0125] Given the microscopic and macroscopic results of this study, it is interesting to consider each biomolecules’ potential mechanism of action and the synergistic characteristics of the combination. Agrin, NRG-1. and ACh have each shown promising nen e regeneration and muscle restoration properties through the Agrin-Lrp4-MuSK signaling pathway as outlined in Figure 1.Not only does each biomolecule contribute to synaptogenesis, neurogenesis and muscle regeneration, but there are synergistic effects between agrin, NRG-1 and ACh that further reinforce their individual therapeutic benefits.39'52To our knowledge, this investigation is the first to use these three biomolecules together as a therapeutic injectable for laryngeal denervation injury.

[0126] The biomolecules agrin, NRG1, and Ach within a gelatin scaffold show promising early outcomes as an injectable treatment for RLN injury. Evidence of nerve regeneration, attenuated muscle atrophy, and functional EMG outcomes outline the robust regenerative capacity of the cocktail. Given the significant response at only 28- days following treatment, further timepoints and applications to other animal models are warranted.

[0127] References1. Sousa F, Santos M, Azevedo S, Pinto A, Vaz Freitas S, Coutinho M, Almeida E Sousa C, Moreira da Silva A. Unilateral Vocal Fold Paralysis and Voice Therapy: Predictors of Long-Term Quality of Life. Cureus. 2023 Jan 23;15(l):e34078. dor 10.7759 / cureus.34078. PMID: 36843683; PMCID: PMC9945010.2. Simpson CB, Cheung EJ, Jackson CJ. Vocal fold paresis: clinical and electrophysiologic features in a tertiary laryngology practice. J Voice. 2009 May;23(3):396-8. doi: 10.1016 / j.jvoice.2007.10.011. Epub 2008 Mar 10. PMID: 18329845.3. Lee DH, Lee SY, Lee Met al. Natural course of unilateral vocal fold paralysis and optimal timing of permanent treatment. JAMA Otolaryngol Head Neck Surg 2020; 146:30-35.4. Wang HW, Lu CC, Chao PZ, Lee FP. Causes of Vocal Fold Paralysis. Ear Nose Throat J 2022; 10LNP294-NP298.5. Elbadan HEM, Hussein WKA, Elmaghraby RM. Transcervical fat injection laryngoplasty for unilateral vocal fold paralysis: an easy way to do the job. Eur Arch Otorhinolaryngol 2017; 274:4161-4167.Atty Docket No. 144578.00484 6. Kimura M, Nito T. Imagawa H, Sakakibara K, Chan RW, Tayama N. Collagen injection for correcting vocal fold asymmetry: high-speed imaging. Ann Otol Rhinol Laryngol. 2010 Jun;l 19(6):359-68. doi: 10.1177 / 000348941011900601. PMID: 20583733.7. Svej dova A, Drsata J, Mejzlik Jet al. Injection laryngoplasty with hyaluronic acid for glottal insufficiency in unilateral vocal fold paralysis: a systematic review of the literature. Eur Arch Otorhinolaryngol 2022; 279:5071-5079.8. Wang TV, Carroll TL. Injection Laryngoplasty and Novel Injectable Materials. Current Otorhinolary ngology Reports 2021; 9:107-112.9. Zimmermann TM, Orbelo DM, Pittelko RL, Youssef SJ, Lohse CM, Ekbom DC. Voice outcomes following medialization laryngoplasty with and without arytenoid adduction. Laryngoscope 2019; 129:1876-1881.10. Philips R, Chorath K, DeSilva B, Forrest LA, Simpson CB, Matrka L. Multi-institutional Evaluation of Medialization Lary ngoplasty' in the Elderly. Otolaryngol Head Neck Surg. 2019 May;160(5):876-884. doi: 10.1177 / 0194599818817762. Epub 2018 Dec 11. PMID: 30526322.11. Aynehchi BB, McCoul ED. Sundaram K. Systematic review of laryngeal reinnervation techniques. Otolaryngol Head Neck Surg 2010; 143:749-759.12. Pei YC, Chang WH, Chuang HF, Chang CF, Fang TJ. Implications of Synkinesis in Unilateral Vocal Fold Paralysis. Otolaryngol Head Neck Surg 2017; 157:1017-1024.13. Halum SL, Hiatt KK. Naidu M, Sufyan AS, Clapp DW. Optimization of autologous muscle stem cell survival in the denervated hemilarynx. Laryngoscope 2008; 118:1308-1312.14. Halum SL, McRae B, Bijangi-Vishehsaraei K, Hiatt K. Neurotrophic factor-secreting autologous muscle stem cell therapy for the treatment of laryngeal denervation injury'. Laryngoscope 2012; 122:2482-2496.15. Halum SL. Naidu M, Delo DM, Atala A. Hingtgen CM. Injection of autologous muscle stem cells (myoblasts) for the treatment of vocal fold paralysis: a pilot study. Laryngoscope 2007; 117:917-922.16. Kaefer SL, Zhang L, Morrison RAet al. Early changes in porcine larynges following injection of motor-endplate expressing muscle cells for the treatment of unilateral vocal fold paralysis. Laryngoscope 2024; 134:272-282.17. Paniello RC, Brookes S, Bhatt NK, Bijangi-Vishehsaraei K, Zhang H, Halum S. Improved adductor function after canine recurrent laryngeal nerve injury' and repair using muscle progenitor cells. Laryngoscope 2018; 128:E241-e246.Atty Docket No. 144578.00484 18. Paniello RC, Brookes S, Zhang H, Halum S. Enhanced Abductor Function in Bilateral Vocal Fold Paralysis with Muscle Stem Cells. Laryngoscope 2024; 134:324-328.19. Shay EO, Morrison RA, Zhang Let al. Scaffold-forming collagen and motor-endplate expressing muscle cells for porcine laryngoplasty. Laryngoscope 2024.20. Halum S. Primed muscle progenitor cells and uses thereof. In: Office USPaT, ed. United States: Purdue Research Foundation, 2022:16.21. Brookes S, Voytik-Harbin S, Zhang H, Halum S. Three-dimensional tissue-engineered skeletal muscle for laryngeal reconstruction. Laryngoscope 2018; 128:603-609.22. Brookes S, Voytik-Harbin S, Zhang H, Zhang L, Halum S. Motor endplate-expressing cartilage-muscle implants for reconstruction of a denervated hemilarynx. Laryngoscope 2019; 129:1293-1300.23. Brookes S, Zhang L, Puls TJ, Kincaid J, Voytik-Harbin S, Halum S. Laryngeal Reconstruction Using Tissue-Engineered Implants in Pigs: A Pilot Study. Laryngoscope 2021; 131:2277-2284.24. Halum SL, Bijangi-Vishehsaraei K, Zhang H. Sowinski J, Bottino MC. Stem cell-derived tissue-engineered constructs for hemilaryngeal reconstruction. Ann Otol Rhinol Laryngol 2014; 123:124-134.25. Wesson T, Zhang L, Morrison RAet al. Tissue-engineered implant for hemilaryngectomy reconstruction with recurrent laryngeal nerve injury. Laryngoscope 2024.26. Halum SL, Bijangi-Vishehsaraei K, Saadatzadeh MR, McRae BR. Differences in laryngeal neurotrophic factor gene expression after recurrent laryngeal nen e and vagus nen e injuries. Ann Otol Rhinol Laryngol 2013; 122:653-663.27. Montalbano MB, Hemandez-Morato I. Tian Let al. Recurrent Laryngeal Nerve Reinnervation in Rats Posttransection: Neurotrophic Factor Expression over Time. Otolaryngol Head Neck Surg 2019; 161 :11 1-117.28. Vega-Cordova X, Cosenza NM, Helfert RH, Woodson GE. Neurotrophin expression of laryngeal muscles in response to recurrent laryngeal nerve transection. Laryngoscope 2010; 120:1591-1596.29. Henze H, Huttner SS, Koch Pet al. Denervation alters the secretome of myofibers and thereby affects muscle stem cell lineage progression and functionality. NPJ Regen Med 2024; 9:10.Atty Docket No. 144578.00484 30. Hakuba N, Tabata Y, Halo N, Fujiwara T, Gyo K. Gelatin hydrogel with basic fibroblast growth factor for tympanic membrane regeneration. Otol Neurotol 2014; 35:540-544.31. Hato N, Nota J, Komobuchi Het al. Facial nerve decompression surgery using bFGF-impregnated biodegradable gelatin hydrogel in patients with Bell palsy. Otolaryngol Head Neck Surg 2012; 146:641-646.32. Imaizumi M. Nakamura R, Nakaegawa Yet al. Regenerative potential of basic fibroblast growth factor contained in biodegradable gelatin hydrogel microspheres applied following vocal fold injury: Early effect on tissue repair in a rabbit model. Braz J Otorhinolaryngol 2021; 87:274-282.33. Haney MM, Hamad A, Woldu HGet al. Recurrent laryngeal nerve transection in mice results in translational upper airway dysfunction. J Comp Neurol 2020; 528:574-596.34. Mok A, Allen J, Haney MMet al. A Surgical Mouse Model for Advancing Laryngeal Nen e Regeneration Strategies. Dysphagia 2020; 35:419-437.35. Bendella H, Rink S, Grosheva M, Sarikcioglu L, Gordon T, Angelov DN. Putative roles of soluble trophic factors in facial nerve regeneration, target reinnervation, and recovery of vibrissal whisking. Exp Neurol 2018; 300:100-110.36. Xu X, Zhuang P, Wilson A, Jiang JJ. Compensatory' Movement of Contralateral Vocal Folds in Patients With Unilateral Vocal Fold Paralysis. J Voice 2021; 35:328 e323-328 e328. 37. Cistema BA, Vargas AA, Puebla Cet al. Active acetylcholine receptors prevent the atrophy of skeletal muscles and favor reinnervation. Nat Commun 2020; 11:1073.38. Kumai Y, Ito T, Matsukawa A, Yumoto E. Effects of denervation on neuromuscular junctions in the thyroary tenoid muscle. Lary ngoscope 2005; 115:1869-1872.39. Hobartner A. Development of a heterologous model system for Agrin-Lrp4-MuSK signaling and analysis of muscle-specific kinase endocytosis. Wien. 2015:94 S. : Ill., graph. Darst.40. Li X, Xu Y, Si JX, Gu F, Ma YY. Role of Agrin in tissue repair and regeneration: From mechanisms to therapeutic opportunities (Review). Int J Mol Med 2024; 54.41. Yang JF, Cao G, Koirala S, Reddy LV, Ko CP. Schwann cells express active agrin and enhance aggregation of acetylcholine receptors on muscle fibers. JNeurosci 2001; 21:9572-9584.42. Zhang BG, Quigley AF, Bourke JLet al. Combination of agrin and laminin increase acetyd choline receptor clustering and enhance functional neuromuscular junction formation In vitro. Dev Neurobiol 2016; 76:551-565.Atty Docket No. 144578.00484 43. Bassat E, Mutlak YE, Genzelinakh Aet al. The extracellular matrix protein agrin promotes heart regeneration in mice. Nature 2017; 547:179-184.44. Hobartner A. Development of a heterologous model system for Agrin-Lrp4-MuSK signaling and analysis of muscle-specific kinase endocytosis. Wien, 2015:94 S. : Ill., graph. Darst.45. Li X, Xu Y, Si JX, Gu F, Ma YY. Role of Agrin in tissue repair and regeneration: From mechanisms to therapeutic opportunities (Review). Int J Mol Med 2024; 54.46. Yang JF, Cao G, Koirala S, Reddy LV, Ko CP. Schwann cells express active agrin and enhance aggregation of acetylcholine receptors on muscle fibers. JNeurosci 2001; 21:9572-9584.47. Zhang BG, Quigley AF, Bourke JLet al. Combination of agrin and laminin increase acetylcholine receptor clustering and enhance functional neuromuscular junction formation In vitro. Dev Neurobiol 2016; 76:551-565.48. Hettwer S, Lin S, Kucsera Set al. Injection of a soluble fragment of neural agrin (NT-1654) considerably improves the muscle pathology caused by the disassembly of the neuromuscular junction. PLoS One 2014; 9:e88739.49. Ngo ST, Cole RN, Sunn N, Phillips WD, Noakes PG. Neuregulin-1 potentiates agrin-induced acetylcholine receptor clustering through muscle-specific kinase phosphorylation. J Cell Sci 2012; 125:1531-1543.50. Li Q, Loeb JA. Neuregulin-heparan-sulfate proteoglycan interactions produce sustained erbB receptor activation required for the induction of acetylcholine receptors in muscle. J Biol Chem. 2001;276:38068-38075. doi: 10.1074 / jbc.M104485200.51. Lopez-Bendito G, Cautinat A, Sanchez JA, et al. Tangential neuronal migration controls axon guidance: a role for neuregulin-1 in thalamocortical axon navigation. Cell. 2006;125:127- 142. doi: 10.1016 / j.cell.2006.01.042.52. Michailov GV. Sereda MW. Brinkmann BG, et al. Axonal neuregulin-1 regulates myelin sheath thickness. Science. 2004;304:700-703. doi: 10.1126 / science.1095862.53. Wang H, Wang H, Li X, Xu W. MuRF-1 is Involved in Laryngeal Muscle Denervation Atrophy by Regulating G- Actin Ubiquitination. Laryngoscope 2024; 134:855-864.54. Foerster G, Podema R, Guntinas-Lichius O, Crumley RL, Mueller AH. Crumley's Classification of Laryngeal Synkinesis: A Comparison of Laryngoscopy and Electromyography. Laryngoscope. 2021 May;131(5):E1605-E1610. doi: 10.1002 / lary.29275. Epub 2020 Nov 21. PMID: 33220002.Atty Docket No. 144578.00484 55. Aljaber MB, Verisqa F, Keskin-Erdogan Z, Patel KD, Chau DYS, Knowles JC. Influence of Gelatin Source and Bloom Number on Gelatin Methacryloyl Hydrogels Mechanical and Biological Properties for Muscle Regeneration. Biomolecules. 2023 May 10;13(5):811. doi: 10.3390 / bioml3050811. PMID: 37238681; PMCID: PMC10216482.Example 2 - Novel Injectable Supports Long-Term Recurrent Laryngeal Nerve and Partial Peripheral Nerve Repair

[0128] Background:Unilateral vocal fold paralysis (VFP) from recurrent laryngeal nerve (RLN) injury currently has no injectable treatment options that promote targeted reinnervation. In a prior pilot study, Agrin, neuregulin-1 (NRGI), and acetylcholine (ACh) enhanced early (1 -month) reinnervation after RLN injury. The aims of the current study were to (1) assess if these effects persist in a 3-month RLN inj ury model and (2) test whether Agrin / ACh / NRGl promotes regeneration after sciatic nerve (SN) transection, with relevance to nerve repair beyond the larynx.

[0129] Methods:Adult C57BL / 6 mice underwent unilateral RLN or SN transection with injections into the thyroarytenoid and gastrocnemius, respectively. Groups included saline (N=5), biomolecule (Agrin, NRGI, ACh) (N=5), and non-injured (normal) controls (N=5). Functional recover}' was evaluated using videolaryngoscopy and electromyography (EMG) for RLN injury’, and gait analysis with EMG for the SN model. Histologic outcomes included immunohistochemistry and myofiber diameter analysis.

[0130] Results:Biomolecule treatment improved vocal fold movement and restored EMG symmetry in the RLN model, consistent with functional reinnervation. Histology demonstrated increased NMJ formation and preserved myofiber integrity'. In the SN model, treatment did not produce meaningful functional recovery based on EMG and gait deficits. However, gross nen e continuity7, increased neurofilament staining, and preserved myofiber architecture indicated partial structural regeneration.

[0131] Conclusions:Biomolecule therapy supports functional and structural regeneration following RLN injury and demonstrates structural, but not sustained functional, recovery in the SN model. FurtherAtty Docket No. 144578.00484 investigation into sustained delivery or repeat dosing may be necessary to support regeneration in larger peripheral nerves.

[0132] Introduction

[0133] Recurrent laryngeal nerve (RLN) injury' is a common cause of unilateral vocal fold paralysis (VFP) and remains a significant source of dysphonia, dysphagia, and impaired airway¬ protection in otolaryngology practice.1-3RLN injury most frequently occurs secondary to cervical and thoracic surgical procedures, trauma, or malignancy.2-4Denervation of the thyroarytenoid (TA) muscle following RLN injury leads to incomplete glottic closure and impaired voice, substantially impacting patient quality of life.13,5Despite advances in surgical management, restoration of coordinated vocal fold motion following RLN injury remains an ongoing clinical challenge.6-7

[0134] Current surgical interventions for VFP primarily improve glottic closure rather than restore intrinsic laryngeal muscle function. Injection laryngoplasty and medialization thyroplasty' reposition the paralyzed vocal fold but do not re-establish physiologic neuromuscular junction (NMJ) architecture or coordinated vocal fold motion.8-11Laryngeal reinnervation techniques attempt to restore adduction. However, outcomes are frequently limited by synkinetic reinnervation and incomplete recovery' of coordinated motor control.712-13The persistence of aberrant reinnervation underscores the need for biologic strategies that promote selective neuromuscular regeneration rather than static medialization alone. Prior investigations by our group have demonstrated that biologically targeted delivery of regenerative biomolecules to the denervated larynx can selectively enhance reinnervation, establishing a framework for injectable biotherapeutic strategies in RLN injury'.6’14-18

[0135] Denervation initiates coordinated axonal and synaptic remodeling. Following transection, distal axons undergo Wallerian degeneration while Schwann cells support axonal elongation toward target muscle fibers.14-13,19Concurrently, loss of neural input results in fragmentation of the postsynaptic apparatus and dispersal of acetylcholine receptors (AChRs).20-21Although axonal regeneration begins within weeks, regenerating axons lack the original topographic cues that directed selective innervation, and newly formed NMJs are initially immature.22-23Incomplete or misdirected reinnervation may therefore occur, leading to synkinesis, particularly in cranial motor nerves such as the RLN w here precise coordination of intrinsic laryngeal musculature is required for normal phonation.7,24Atty Docket No. 144578.00484

[0136] Functional NMJs are governed by well-established signaling pathways. Agrin activates the muscle-specific kinase (MuSK) receptor complex to induce clustering of AChRs at the postsynaptic membrane.25-27Neuregulin-1 (NRG1) signaling regulates acetylcholine receptor transcription and Schwann cell-mediated axonal guidance.28-29Activity-dependent acetylcholine (ACh) signaling contributes to synaptic stabilization and maturation.20-21Together, these pathways are reactivated following nerve injury and represent potential targets for enhancing selective motor reinnervation.30-32

[0137] Co-injection of Agrin, NRG1, and ACh into denervated TA muscle was previously shown to enhance early (1 -month) structural and electrophysiologic evidence of reinnervation following RLN transection.33However, early outcomes may not translate into durable functional recovery’. Synaptic maturation and functional or maladaptive synkinetic pathways evolve over several months following nerve injury'.7’22,34Accordingly, evaluation at three months allows assessment beyond the acute regenerative phase to assess long-term RLN recovery' in a murine model. A goal of the current study was also to determine whether biomolecular augmentation of regeneration extends beyond the laryngeal environment. The sciatic nerve (SN) transection model was therefore selected as a well-characterized system for quantifying axonal regeneration and functional recovery.35 36While the molecular pathways governing NMJ assembly share conserved signaling components across motor nerve systems, the relative contribution of NMJ-directed versus axon-growth-directed mechanisms may vary’ based on nerve size and injury’ context.19,29,30,37,38,39

[0138] The goal of the current study was to (1) determine whether localized administration of Agrin, NRG1, and ACh produces sustained structural and functional reinnervation in a three-month RLN injury model, and (2) evaluate whether this biomolecular strategy’ promotes peripheral nerve regeneration beyond the laryngeal microenvironment. We hypothesized that targeted modulation of NMJ-associated signaling pathways by Agrin, NRG1, and Ach would promote stable NMJ formation and enhance axonal regeneration following RLN and SN injury in a murine model. FIG.9 outlines the nerve injury models, experimental timeline, and treatment groups.

[0139] Materials and Methods

[0140] Injection Preparation

[0141] The biomolecule treatment consisted of 500 nM agrin (Catalog# 6624-AG, R&D Systems, Minneapolis, Minnesota), 1 nM neuregulin-1 (Catalog# 5898-NR, R&D Systems, Minneapolis, Minnesota), and 100 pM acetylcholine chloride (Catalog# 159170050, Thermo Scientific, FairAtty Docket No. 144578.00484 Lawn, New Jersey) in sterile 0.9% saline. Injections were prepared one week prior to surgery and identical formulations were used for both RLN and SN experiments.

[0142] Survival Surgery

[0143] All procedures w ere performed in accordance w ith an lACUC-approved protocol (23150). Male C57BL / 6 mice were housed at the Laboratory Animal Resource Center (LARC) at Indiana University under standard conditions with a 72-hour acclimation period prior to experimental manipulation. Mice were allocated to one of three groups: (1) non-injured (normal) control, (2) saline control, and (3) biomolecule treatment. For injured groups, Day 0 was defined as the date of nerve transection. For the uninjured normal cohort, Day 0 corresponded to the date of arrival following acclimation.

[0144] For the RLN model, mice in the saline (n=5) and biomolecule (n=5) groups underwent survival surgery in which the right RLN was exposed through a ventral cervical approach and transected at the level of the fourth to sixth tracheal ring. Vocal fold immobility7was confirmed via video laryngoscopy. A single 10 pL injection of assigned treatment was delivered transcartilaginously into the right thyroarytenoid muscle. For the SN model, the left SN was exposed through a posterior thigh incision and transected 3-6 mm proximal to the sciatic trifurcation. Treatment was administered via dual delivery: 40 pL injected into the gastrocnemius muscle belly and 10 pL applied directly to the transected nerve site. Mice were followed longitudinally and harvested at 28-day and 84-day time points.

[0145] Laryngeal Testing

[0146] Transoral video laryngoscopy (Ambu aScope 5 Broncho 2.7 / 1.2 mm, Catalog# 624001000US, Ambu, Columbia, Maryland) was performed to assess vocal fold motion and positioning before and after RLN transection. At harvest, baseline spontaneous vocal fold movement was assessed, followed by independent stimulation of the right and left RLNs to evaluate stimulation-induced vocal fold twitching as a measure of functional reinnervation.

[0147] Electromyography

[0148] EMG was performed at harvest in both models using the UltraPro SI 00 EMG system (Catalog# 828-060800, Natus, Middleton, Wisconsin). For the RLN model, the right and left RLNs were stimulated independently at 5.10 mA and 1 Hz, with recordings obtained from the ipsilateral TA muscle. Area under the curve (AUC) values were calculated for quantitative comparison between treatment groups. For the sciatic model, baseline EMG was recorded prior to transection and repeated at harvest for the injured left and contralateral right hindlimb. The SN was stimulatedAtty Docket No. 144578.00484 at 1.18 mA and 1 Hz, with evoked responses recorded from the gastrocnemius muscle and AUC values calculated for each recording.

[0149] Sciatic Functional Assessment

[0150] Gait was assessed using the Kinetic Weight Bearing system (BIO-KWB-DUAL, Bioseb, Vitrolles, France). Mice underwent two habituation sessions prior to surgery. Assessments were performed pre-operatively (Day 0) and post-operatively on Days 3 and 7, then weekly until harvest. During each session, mice traversed the chamber corridor freely for a 5-minute period without external motivation. A compliant run was defined as uninterrupted forward movement generating 10-30 valid paw prints, with at least three compliant runs obtained per session. Automated recordings were manually reviewed to confirm paw assignment accuracy. Limb-specific variables including peak force, force curve area, stance duration, propulsion duration, and stride length were collected for each hindlimb. Injured left limb values were compared to contralateral right limb values to quantify interlimb asymmetry.

[0151] Histology and Immunohistochemistry

[0152] For RLN analysis, larynges were harvested following euthanasia, fixed in 10% neutral buffered formalin for 24 hours, embedded in HistoGel (Catalog# HG-4000-012, Richard-Allan Scientific, Kalamazoo, MI), and processed by the Indiana Universify Histology Core. Tissues were paraffin-embedded and sectioned at 5 pm. Immunohistochemical staining was performed to evaluate neuromuscular junction integrity and nerve regeneration; antibody sources and staining protocols are provided in Supplemental Information. Myofiber diameter was quantified from scanned H&E images using Aperio ImageScope (Leica, Deer Park, Illinois). Fifty myofibers were randomly sampled from the right and left thyroarytenoid muscles independently for analysis.

[0153] For sciatic analysis, gastrocnemius muscles were harvested, fixed in 10% neutral buffered formalin for 24 hours, transferred to 70% ethanol, and processed by the Indiana University Histology Core. Specimens were paraffin-embedded and sectioned at 5 pm in both cross-sectional and longitudinal orientations. The same immunohistochemical assays were applied. Myofiber diameter was quantified from digitized H&E cross-sectional images in FIJI (ImageJ) using morphological gradient-based watershed segmentation (MorphoLibJ plugin). Minimum Ferefs diameter was calculated per fiber, filtered to exclude non-myofiber segments based on size and shape parameters, and averaged per specimen for analysis.

[0154] Statistical AnalysisAtty Docket No. 144578.00484

[0155] Statistical analyses were performed using R (R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was defined as a = 0.05.

[0156] Electromyography

[0157] Recovery was assessed by paired t-test comparing injured versus contralateral AUC within each treatment group. Between-group differences were assessed by independent t-test. This approach was applied to both RLN and sciatic EMG analyses.

[0158] Gait and Functional Assessment

[0159] Longitudinal gait and weight-bearing parameters were analyzed using linear mixed-effects modeling with treatment, time, and their interaction as fixed effects and a random intercept per animal to account for repeated measures. Post-hoc pairwise comparisons were performed with Tukey adjustment for multiple comparisons. Limb symmetry recovery was assessed by comparing the injured-to-contralateral force curve area ratio against a reference value of 1.0 using one-sample t-tests.

[0160] Video Laryngoscopy

[0161] Vocal fold motion and positioning scores were compared across groups using the Kruskal-Wallis test with Dunn post-hoc comparisons and Benjamini-Hochberg correction.

[0162] Histologic Quantification

[0163] Normality was assessed using the Shapiro-Wilk test. Myofiber diameter was compared between groups using Welch's ANOVA with Games-Howell post-hoc analysis.

[0164] Results

[0165] Functional Outcomes

[0166] Video Laryngoscopy

[0167] Right RLN stimulation resulted in a right vocal fold response in 4 / 5 biomolecule mice compared to 0 / 5 saline mice (p = 0.019), while all 5 / 5 normal mice responded. Left RLN stimulation responses were intact across all groups (5 / 5), confirming injury specificity to the right RLN. At 84 days, 3 / 5 biomolecule mice demonstrated midline vocal fold positioning compared to 0 / 5 saline mice, which showed predominantly lateralized or abducted positioning (p = 0.076). Partial spontaneous movement was observed in 4 / 5 biomolecule mice compared to 0 / 5 saline mice (p = 0.002). FIG. 10 displays representative 84-day video laryngoscopy images from the normal, saline, and biomolecule groups. Blinded vi deol aryngos copy scoring across all animals is shown in FIG. 17

[0168] Stimulated EMGAtty Docket No. 144578.00484

[0169] At 84 days, paired analysis of right (injured) versus left (uninjured) stimulated RLN EMG demonstrated no significant difference in AUC between sides in the biomolecule group (p = 0.177), indicating restoration of symmetry between the injured and uninjured RLN. In contrast, the saline group showed a significant right-sided deficit at 84 days (p = 0.031), consistent with persistent denervation of the injured RLN. No significant side difference was observed in the normal group (p = 0.325). In the SN model, both biomolecule and saline groups demonstrated significant asymmetry between injured and uninjured sides at 28 days (p = 0.001 and p = 0.023, respectively), which persisted at 84 days (p = 0.009 and p = 0.038), suggesting incomplete peripheral nerve recovery at these timepoints. FIG. 11 shows (A) quantitative AUC differences between injured and uninjured RLNs at 84 days and (B) gross images of the regenerated RLN nerve band at harvest, which was present in all biomolecule-treated animals. FIG. 12 shows stimulated SN EMG findings at 28 and 84 days, demonstrating persistent asymmetry between injured and uninjured sides across timepoints.

[0170] Gait Analysis

[0171] All groups demonstrated a sharp decline in FCA ratio by day 3 following SN transection, confirming successful injury. Both the biomolecule and saline groups remained significantly below a ratio of 1.0 at all timepoints through 84 days, and significantly below the normal group throughout the observation period, indicating persistent gait asymmetry7without meaningful recovery in either group. The biomolecule group showed a trend toward transient improvement on day 14 (p = 0.068 vs. 1.0), representing the closest approach to symmetry observed across all timepoints, though this did not reach statistical significance. FIG. 13 displays FCA ratio over time for the biomolecule, saline, and normal groups.

[0172] Histopathological Analysis

[0173] Immunohistochemistry

[0174] FIG. 14 demonstrates immunofluorescent staining of the TA muscle at 84 days following RLN transection. Combined CHRNA1 / SV2 / NF-L staining showed increased co-localization of presynaptic and postsynaptic neuronal structures in the biomolecule-treated group relative to saline, consistent with increased presence of innervated neuromuscular junctions (NMJs). Comparative staining across groups demonstrated the highest NMJ density in normal animals, reduced staining in saline, and intermediate preservation in the biomolecule group, suggesting treatment-mediated maintenance of NMJ integrity.Atty Docket No. 144578.00484

[0175] In the SN model, gross evaluation demonstrated improved continuity of the transected nerve in the biomolecule-treated group compared to saline. Nerve continuity was observed in 5 / 5 biomolecule-treated animals at 28 days and in 4 / 5 animals at 84 days. Corresponding NF -L staining of gastrocnemius-associated nerve tissue demonstrated reduced neuronal signal in saline-treated animals relative to normal, while the biomolecule group showed increased NF-L positive fibers compared to saline, consistent with partial axonal regeneration (FIG. 15).

[0176] Myofiber Diameter

[0177] At 84 days, the TA muscle myofiber diameter right-to-left ratio was significantly greater in the biomolecule group compared to the saline group (p = 0.015), indicating preservation of muscle fiber symmetry with biomolecule treatment. The saline group demonstrated a significantly reduced ratio compared to normal controls (p = 0.004), consistent with atrophy of the injured right TA muscle. In contrast, the biomolecule group did not differ significantly from normal (p = 0.672), suggesting restoration of myofiber integrity. FIG. 16 displays right-to-left myofiber diameter ratios across groups.

[0178] In the sciatic nerve model, both saline and biomolecule-treated groups demonstrated reduced right-to-left myofiber diameter asymmetry at 28 days (saline: p = 0.009, biomolecule: p = 0.020). At 84 days, saline-treated animals continued to exhibit significant asymmetry (p = 0.035), while the biomolecule group demonstrated a trend toward restoration of limb symmetry (p = 0.053).FIG. 18 displays right-to-left myofiber diameter ratios at 28 and 84 days, with a representative image of morphologic segmentation.

[0179] Discussion

[0180] This study evaluated the functional, histologic, and structural effects of Agrin, NRG1, and ACh biomolecule treatment following nerve injury in RLN and SN models. In the RLN model, biomolecule therapy supported functional reinnervation, NMJ preservation, and maintenance of neuromuscular structure through 84 days. In contrast, although early (28-day) structural and histologic signs of regeneration were observed after SN transection, these changes did not translate into functional recovery, underscoring fundamental differences in regenerative requirements between the two systems.40-42

[0181] RLN Model: Functional, Histologic, and Structural Recovery

[0182] Biomolecule treatment improved functional outcomes in the RLN model, demonstrated by restored vocal fold movement, enhanced response to RLN stimulation (FIG. 10), and improved EMG symmetry relative to saline controls (FIG. 11). Histologically, biomolecule-treated TAAtty Docket No. 144578.00484 muscle showed increased co-localization of NF-L, SV2, and CHRNA1, consistent with preservation or reformation of innervated NMJs (FIG. 14). Gross visualization of the regenerated RLN and attenuation of TA myofiber atrophy further support maintenance of neuromuscular structural integrity (FIG. 16).

[0183] The functional improvements likely arise from two complementary mechanisms. First, biomolecule exposure induces release of regenerative neurotrophic and angiogenic factors from the injected muscle, as demonstrated in prior in vivo and in vitro studies.18,43-44Second, NRG1 -mediated ErbB activation promotes Schwann cell transition to a repair phenotype, facilitating axonal regeneration.29-31At the NMJ, Agrin stabilizes the postsy naptic apparatus through Lrp4-MuSK signaling, while NRG1 enhances AChR transcription via ErbB activation.25-31ACh may further support early synaptic maintenance by binding residual receptors during denervation.20Together, these mechanisms create a microenvironment that preserves NMJ architecture, promotes targeted reinnervation, and supports functional recovery in the RLN model.

[0184] SN Model: Lack of Functional Recovery Despite Partial Histologic and Structural Reinnervation

[0185] In the SN model, both biomolecule-treated and saline-treated animals exhibited persistent functional deficits, with no improvement in EMG symmetry (FIG. 12) or gait parameters (FIG.13). Nonetheless, biomolecule-treated nerves demonstrated early structural indicators of regeneration, including gross continuity, increased NF-L-positive fibers, and partial preservation of myofiber architecture (FIG. 15).

[0186] This dissociation between structure and function reflects the markedly different regenerative demands of the two models. Whereas RLN injury' is followed by relatively short-distance, target-specific reinnervation, the unrepaired sciatic nerve complete transection represents a stringent negative control and the most severe form of peripheral nerve injury. Its large diameter, mixed sensory-motor composition, and the substantial spontaneous gap that forms after transection create conditions under which spontaneous functional recovery' is exceedingly unlikely.

[0187] The early continuity' at 28 days likely reflects initial mechanical and trophic support provided by the biomolecule injection, including early formation of Bands of Bungner and Schwann cell transition to a repair phenotype through ErbB-dependent signaling.29-31With single injection administration, however, structural and nutritional support were not sustained. By 84 days, fewer biomolecule-treated nerves maintained continuity, indicating loss of structural stability over time. In a mobile limb, where the sciatic nerve experiences substantial mechanical strain, earlyAtty Docket No. 144578.00484 bridging tissue may regress or remodel unfavorably, preventing maturation of functional connections. These findings indicate that while the biomolecules promote early regenerative events, successful long-distance regeneration in a large peripheral nerve will require prolonged or repeated support, which was not provided in this single-dose paradigm.

[0188] Limitations

[0189] This study is limited by using a small animal model and modest sample size. Immunohistochemical findings were not quantitatively assessed, and future studies incorporating quantitative axonal metrics are being planned to strengthen these observations. Additionally, the SN model represents an extreme peripheral nerve injury paradigm that may not fully replicate the regenerative characteristics of other nerve systems.

[0190] Conclusions

[0191] Biomolecule therapy consisting of Agrin, NRG1, and Ach demonstrates strong potential as an injectable treatment for RLN injury, promoting functional reinnervation, NMJ preservation, and maintenance of muscle integrity through 84 days. Although early structural regeneration was observed in the SN model, these findings did not translate into functional recovery, likely reflecting the greater demands of long-distance axonal regeneration compared with the more localized, target-specific reinnervation of the RLN. Future work incorporating sustained-release delivery, repeat dosing, or less severe injury paradigms will be necessary to enhance outcomes in peripheral nerve models requiring prolonged axonal regeneration.

[0192] References for Example 21. Sousa F, Santos M, Azevedo S, Pinto A, Vaz Freitas S, Coutinho M, Almeida E Sousa C, Moreira da Silva A. Unilateral Vocal Fold Paralysis and Voice Therapy:Predictors of Long-Term Quality of Life. Cureus. 2023 Jan 23;15(l):e34078. doi:10.7759 / cureus.34078. PMID: 36843683; PMCID: PMC9945010. Simpson CB, Cheung EJ, Jackson CJ. Vocal fold paresis: clinical and electrophysiologic features in a tertiary laryngology practice. J Voice. 2009;23(3):396-398.2. Simpson CB, Cheung EJ, Jackson CJ. Vocal fold paresis: clinical and electrophysiologic features in a tertiary laryngology practice. J Voice. 2009 May;23(3):396-8. doi: 10.1016 / j.jvoice.2007.10.011. Epub 2008 Mar 10. PMID: 18329845.3. Lee DH, Lee SY, Lee M, Seok J. Park SJ, Jin YJ, Lee DY, Kwon TK. Natural Course of Unilateral Vocal Fold Paralysis and Optimal Timing of Permanent Treatment.JAMA Otolaryngol Head Neck Surg. 2020 Jan 1 ; 146(1 ): 30-35. doi:10.1001 / jamaoto.2019.3072. PMID: 31750869; PMCID: PMC6902150.Atty Docket No. 144578.00484 4. Wang HW, Lu CC, Chao PZ, Lee FP. Causes of Vocal Fold Paralysis. Ear Nose Throat J. 2022 Aug;101(7):NP294-NP298. doi: 10.1177 / 0145561320965212. Epub 2020 Oct 22. PMID: 33090900.5. Francis DO, Sherman AE, Hovis KL, Bonnet K. Schlundt D, Garrett CG, Davies L. Life Experience of Patients With Unilateral Vocal Fold Paralysis. JAMA Otolaryngol Head Neck Surg. 2018 May l;144(5):433-439. doi: 10.1001 / jamaoto.2018.0067. PMID: 29621392; PMCID: PMC6136051.6. Halum SL, Hiatt KK. Naidu M, Sufyan AS, Clapp DW. Optimization of autologous muscle stem cell survival in the denervated hemilarynx. Lary ngoscope. 2008 Jul;l 18(7): 1308-12. doi: 10.1097 / MLG.0b013e31816c438e. PMID: 18401272.7. Aynehchi BB, McCoul ED, Sundaram K. Systematic review of laryngeal reinnervation techniques. Otolary ngol Head Neck Surg. 2010 Dec;143(6):749-59. doi:10.1016 / j.otohns.2010.09.031. PMID: 21109073.8. Elbadan HEM, Hussein WKA, Elmaghraby RM. Transcervical fat injection laryngoplasty for unilateral vocal fold paralysis: an easy way to do the job. Eur Arch Otorhinolaryngol. 2017 Dec;274(12):4161-4167. doi: 10.1007 / s00405-017-4758-6. Epub 2017 Oct 6. PMID: 28986671.9. Kimura M, Nito T, Imagawa H, Sakakibara K. Chan RW, Tayama N.Collagen injection for correcting vocal fold asymmetry: high-speed imaging. Ann Otol Rhinol Laryngol. 2010 Jun;119(6):359-68. doi: 10.1177 / 000348941011900601. PMID: 20583733.10. Svejdova A, Drsata J, Mejzlik J, Homolac M, Krtickova J, Satankova J.Chrobok V. Injection lary ngoplasty7with hyaluronic acid for glottal insufficiency in unilateral vocal fold paralysis: a systematic review of the literature. Eur Arch Otorhinolaryngol. 2022 Nov;279(l I):5071-5079. doi: 10.1007 / s00405-022-07437-0. Epub 2022 Jun 29. PMID: 35767054.11. Wang, T.V., Carroll, T.L. Injection Lary ngoplasty7and Novel Injectable Materials. Curr Otorhinolaryngol Rep 9, 107-112 (2021)- https: / / doi.org / 10.1007 / s40136-021-00331-z12. Zimmermann TM, Orbelo DM, Pittelko RL, Youssef SJ, Lohse CM, Ekbom DC. Voice outcomes following medialization lary ngoplasty7with and without ary tenoid adduction. Laryngoscope. 2019 Aug;129(8):1876-1881. doi: 10.1002 / lary.27684. Epub 2018 Dec 24. PMID: 30582612.13. Philips R, Chorath K, DeSilva B, Forrest LA, Simpson CB, Matrka L. Multi-institutional Evaluation of Medialization Laryngoplasty in the Elderly. Otolaryngol Head Neck Surg. 2019 May;160(5):876-884. doi: 10.1177 / 0194599818817762. Epub 2018 Dec 11. PMID: 30526322.14. Halum SL, Naidu M, Delo DM, Atala A, Hingtgen CM. Injection of autologous muscle stem cells (myoblasts) for the treatment of vocal fold paralysis: a pilot study. Laryngoscope. 2007 May;117(5):917-22. doi: 10.1097 / MLG.0b013e31803e8c8d. PMID: 17473696.Atty Docket No. 144578.00484 15. Halum SL, McRae B, Bijangi-Vishehsaraei K, Hiatt K. Neurotrophic factorsecreting autologous muscle stem cell therapy for the treatment of laryngeal denervation injury. Laryngoscope. 2012 Nov;122(ll):2482-96. doi: 10.1002 / lary.23519. Epub 2012 Sep 10. PMID: 22965802; PMCID: PMC3484207.16. Halum SL, Bijangi-Vishehsaraei K, Saadatzadeh MR, McRae BR. Differences in laryngeal neurotrophic factor gene expression after recurrent laryngeal nerve and vagus nerve injuries. Ann Otol Rhinol Laryngol. 2013 Oct;122(10):653-63. PMID: 24294689.17. Paniello RC, Brookes S, Bhatt NK, Bijangi-Vishehsaraei K, Zhang H, Halum S. Improved adductor function after canine recurrent laryngeal nerve injury’ and repair using muscle progenitor cells. Laryngoscope. 2018 Jul;128(7):E241-E246. doi: 10.1002 / lary.26992. Epub 2017 Dec 8. PMID: 29219186; PMCID: PMC6661170.18. Kaefer SL, Zhang L, Morrison RA, Brookes S, Awonusi O, Shay E, Hoilett OS, Anderson JL, Goergen CJ, Voytik-Harbin S, Halum S. Early Changes in Porcine Larynges Following Injection of Motor-Endplate Expressing Muscle Cells for the Treatment of Unilateral Vocal Fold Paralysis. Laryngoscope. 2024 Jan;134(l):272-282. doi:10.1002 / lary.30868. Epub 2023 Jul 12. PMID: 37436167; PMCID: PMC11790276.19. Gordon T. Peripheral Nerve Regeneration and Muscle Reinnervation. Int J Mol Sci. 2020 Nov 17:21(22): 8652. doi: 10.3390 / ijms21228652. PMID: 33212795; PMCID: PMC7697710.20. Cistema BA, Vargas AA, Puebla C, Fernandez P, Escamilla R, Lagos CF, Matus MF, Vilos C, Cea LA, Bamafi E, Gaete H, Escobar DF, Cardozo CP, Saez JC. Active acetylcholine receptors prevent the atrophy of skeletal muscles and favor reinnervation. Nat Commun. 2020 Feb 26;11(1): 1073. doi: 10.1038 / s41467-019-14063-8. PMID: 32103010; PMCID: PMC7044284.21. Kumai Y, Ito T, Matsukawa A. Yumoto E. Effects of denervation on neuromuscular junctions in the thyroarytenoid muscle. Laryngoscope. 2005Oct; 115(10): 1869-72. doi: 10.1097 / 01. mlg.0000177076.33294.89. PMID: 16222212.22. Montalbano MB, Hemandez-Morato I, Tian L, Yu VX, Dodhia S, Martinez J, Pitman MJ. Recurrent Laryngeal Nerve Reinnervation in Rats Posttransection: Neurotrophic Factor Expression over Time. Otolaryngol Head Neck Surg. 2019 Jul;161(l): 111-117. doi: 10.1177 / 0194599819831289. Epub 2019 Feb 19. PMID: 30776993.23. Vega-Cordova X, Cosenza NM, Helfert RH, Woodson GE. Neurotrophin expression of laryngeal muscles in response to recurrent laryngeal nerve transection.Laryngoscope. 2010 Aug;120(8): 1591-6. doi: 10.1002 / laiy.21026. PMID: 20641073.24. Pei YC, Chang WH, Chuang HF, Chang CF, Fang TJ. Implications of Synkinesis in Unilateral Vocal Fold Paralysis. Otolaryngol Head Neck Surg. 2017 Dec;157(6): 1017-1024. doi: 10.1177 / 0194599817721688. Epub 2017 Aug 1. PMID:28762290.25. Li X, Xu Y, Si JX, Gu F, Ma YY. Role of Agrin in tissue repair and regeneration: From mechanisms to therapeutic opportunities (Review). Int J Mol Med. 2024Atty Docket No. 144578.00484 Nov;54(5):98. doi: 10.3892 / ijmm.2024.5422. Epub 2024 Sep 20. PMID: 39301653; PMCID: PMC11410309.26. Yang JF, Cao G, Koirala S, Reddy LV, Ko CP. Schwann cells express active agrin and enhance aggregation of acetylcholine receptors on muscle fibers. J Neurosci. 2001 Dec 15;21(24):9572-84. doi: 10.1523 / JNEUROSCI.21-24-09572.2001. PMID: 11739568; PMCID: PMC 6763019.27. Zhang BG, Quigley AF, Bourke JL, Nowell CJ, Myers DE, Choong PF, Kapsa RM. Combination of agrin and laminin increase acetylcholine receptor clustering and enhance functional neuromuscular junction formation In vitro. Dev Neurobiol. 2016 May;76(5):551-65. doi: 10.1002 / dneu.22331. Epub 2015 Aug 21. PMID: 26251299.28. Lopez-Bendito G, Cautinat A, Sanchez JA, Bielle F. Flames N, Garratt AN, Talmage DA, Role LW, Chamay P, Marin O, Garel S. Tangential neuronal migration controls axon guidance: a role for neuregulin-1 in thalamocortical axon navigation. Cell. 2006 Apr 7;125(1): 127-42. doi: 10.1016 / j.cell.2006.01.042. PMID: 16615895; PMCID: PMC2365888.29. Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA. Axonal neuregulin-1 regulates myelin sheath thickness. Science. 2004 Apr 30;304(5671):700-3. doi: 10.1126 / science.1095862. Epub 2004 Mar 25. PMID: 15044753.30. Ngo ST, Cole RN, Sunn N, Phillips WD, Noakes PG. Neuregulin-1 potentiates agrin-induced acetylcholine receptor clustering through muscle-specific kinase phosphorylation. J Cell Sci. 2012 Mar 15;125(Pt 6): 1531-43. doi: 10.1242 / jcs.095109. Epub 2012 Feb 10. PMID: 22328506.31. Li Q, Loeb JA. Neuregulin-heparan-sulfate proteoglycan interactions produce sustained erbB receptor activation required for the induction of acetylcholine receptors in muscle. J Biol Chem. 2001 Oct 12;276(41):38068-75. doi: 10.1074 / jbc.M104485200. Epub 2001 Aug 13. PMID: 11502740.32. Hettwer S, Lin S, Kucsera S et al. Injection of a soluble fragment of neural agrin (NT- 1654) considerably improves the muscle pathology caused by the disassembly of the neuromuscular junction. PLoS One. 2014;9(2):e88739.33. Tadikonda A, Anekal S, Chen LW, Sobczak G, Wesson T, Jackson C, Egan MA, Liu JC, Finnegan PR, Halum S. Novel Biomolecule-Infused Gelatin Injectable for Treatment of Recurrent Laryngeal Nerve Injury. Laryngoscope. 2025 Dec;135(12):4781-4792. doi: 10.1002 / lary.32459. Epub 2025 Sep 15. PMID: 40952065; PMCID:PMC 12706572.34. Bendella H, Rink S, Grosheva M, Sarikcioglu L. Gordon T, Angelov DN. Putative roles of soluble trophic factors in facial nerve regeneration, target reinnervation, and recovery of vibrissal whisking. Exp Neurol. 2018 Feb;300: 100-110. doi:10.1016 / j.expneurol.2017.10.029. Epub 2017 Nov 8. PMID: 29104116.Atty Docket No. 144578.00484 35. Geuna S. The sciatic nerve injury model in pre-clinical research. J Neurosci Methods. 2015 Mar 30;243:39-46. doi: 10.1016 / j.jneumeth.2015.01.021. Epub 2015 Jan 25. PMID: 25629799.36. Savastano LE, Laurito SR, Fitt MR, Rasmussen JA, Gonzalez Polo V, Patterson SL Sciatic nerve injury: a simple and subtle model for investigating many aspects of nervous system damage and recover}7. J Neurosci Methods. 2014 Apr 30;227: 166-80. doi: 10.1016 / j.jneumeth.2014.01.020. Epub 2014 Jan 30. PMID: 24487015.37. Ten Asbroek AL. Van Ruissen F, Ruijter JM, Baas F. Comparison of Schwann cell and sciatic nene transcriptomes indicates that mouse is a valid model for the human peripheral nervous system. J Neurosci Res. 2006 Aug 15;84(3):542-52. doi:10.1002 / jnr.20966. PMID: 16786575.38. Mok A, Allen J, Haney MM, Deninger I, Ballenger B, Caywood V, Osman KL, Zitsch B, Hopewell BL, Thiessen A, Szewczyk M, Ohlhausen D, Newberry CI, Leary E, Lever TE. A Surgical Mouse Model for Advancing Laryngeal Nerve Regeneration Strategies. Dysphagia. 2020 Jun;35(3):419-437. doi: 10.1007 / s00455-019-10045-6. Epub 2019 Aug 6. PMID: 31388736; PMCID: PMC8344066.39. Haney MM, Hamad A, Woldu HG, Ciucci M, Nichols N, Bunyak F, Lever TE. Recurrent laryngeal nerve transection in mice results in translational upper airway dysfunction. J Comp Neurol. 2020 Mar l;528(4):574-596. doi: 10.1002 / cne.24774. Epub 2019 Oct 18. PMID: 31512255; PMCID: PMC7018444.40. Mahar M, Cavalli V. Intrinsic mechanisms of neuronal axon regeneration. Nat Rev Neurosci. 2018 Jun;19(6):323-337. doi: 10.1038 / s41583-018-0001-8. PMID: 29666508; PMCID: PMC5987780.41. Huang DX, Yang MX, Jiang ZM, Chen M, Chang K, Zhan YX, Gong X. Nerve trunk healing and neuroma formation after nerve transection injury . Front Neurol. 2023 Jun 12;14:1184246. doi: 10.3389 / fneur.2023.1184246. PMID: 37377855; PMCID: PMC10291201.42. Grossmann KS, Wende H, Paul FE, Cheret C, Garratt AN, Zurborg S, Feinberg K, Besser D, Schulz H, Peles E, Selbach M, Birchmeier W, Birchmeier C. The tyrosine phosphatase Shp2 (PTPN11) directs Neuregulin-l / ErbB signaling throughout Schwann cell development. Proc Natl Acad Sci U S A. 2009 Sep 29; 106(39): 16704-9. doi: 10.1073 / pnas.0904336106. Epub 2009 Sep 11. PMID: 19805360; PMCID: PMC2742405.43. Shay EO, Morrison RA, Zhang L, Kaefer SL, Wesson T, Cox A, Voytik-Harbin SL, Halum S. Scaffold-Forming Collagen and Motor-Endplate Expressing Muscle Cells for Porcine Laryngoplasty. Laryngoscope. 2024 Dec;134(12):4988-4997. doi:10.1002 / lary.31642. Epub 2024 Jul 16. PMID: 39011835.44. Kaefer SL, Zhang L, Brookes S, Morrison RA, Voytik-Harbin S, Halum S. Optimizing transport methods to preserve function of self-innervating muscle cells for laryngeal injection. Laryngoscope Investig Otolaryngol. 2024 Dec 8;9(6):el259. doi:10.1002 / lio2.1259. PMID: 39655095; PMCID: PMC11625686.Atty Docket No. 144578.00484 45. Lindmar R, Ldffelholz K, Weide W. Interstitial washout and hydrolysis of acety lcholine in the perfused heart. Naunyn Schmiedebergs Arch Pharmacol. 1982 Mar;318(4):295-300. doi: 10.1007 / BF00501168. PMID: 7078663.46. Bezakova G, Helm JP, Francolini M, Lomo T. Effects of purified recombinant neural and muscle agrin on skeletal muscle fibers in vivo. J Cell Biol. 2001 Jun 25;153(7):1441-52. doi: 10.1083 / jcb.153.7.1441. PMID: 11425874; PMCID: PMC2150725.47. Yasui G, Yamamoto Y, Shichinohe R, Funayama E, Oyama A, Hayashi T, Furukawa H. Neuregulin-1 released by biodegradable gelatin hydrogels can accelerate facial nerve regeneration and functional recovery7of traumatic facial nerve palsy. J Plast Reconstr Aesthet Surg. 2016 Mar;69(3):328-34. doi: 10.1016 / j bjps.2015.10.037. Epub 2015 Oct 30. PMID: 26631289.

[0193] In the foregoing description, it will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention. Thus, it should be understood that although the present invention has been illustrated by specific embodiments and optional features, modification and / or variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.

[0194] Citations to a number of patent and non-patent references may be made herein. The cited references are incorporated by reference herein in their entireties. In the event that there is an inconsistency betw een a definition of a term in the specification as compared to a definition of the term in a cited reference, the term should be interpreted based on the definition in the specification.

Claims

Atty Docket No. 144578.00484CLAIMSWe claim:

1. A method of treating peripheral nerve injury in a subject comprising administering a composition comprising agrin, neuregulin (NRG1 ). and acetylcholine (ACh) to the subject.

2. The method of claim 1 , wherein the peripheral nerve is the recurrent laryngeal nerve (RLN).

3. The method of claim 1, wherein the composition is administered to the subject via injection, optionally injection into muscle.

4. The method of claim 2, wherein muscle atrophy in the subject is attenuated.

5. The method of claim 2, wherein glottic function in the subject is restored.

6. The method of claim 1, wherein the peripheral nerve is the sciatic nerve.

7. The method of claim 1, wherein the composition further comprises a collagen scaffold, optionally, wherein the collagen scaffold is a gelatin scaffold.

8. The method of claim 1, wherein the concentration of agrin is about 50 nM to about 5000 nM in the composition.

9. The method of claim 1, wherein the concentration of NRG1 is about 0.1 nM to about 100 nM in the composition.

10. The method of claim 1, wherein the concentration of Ach is about 10 micromolar to about 1000 micromolar.

11. The method of claim 1 , wherein the concentration of agrin is about 500 nM, the concentration of NRG is about 1 nM, and the concentration of ACh is about 100 micromolar.

12. The method of claim 1 , wherein the composition is administered to the subject via injection, optionally injection into muscle.

13. The method of claim 1, wherein the composition is administered into the thyroarytenoid (TA) muscle.

14. The method of claim 1, wherein the composition is administered once to the subject.Atty Docket No. 144578.00484 15. The method of claim 1, wherein the composition is administered multiple times to the subject.

16. A method of increasing neuronal regeneration and reinnervation after RLN injury’ in a subject, comprising administering a composition comprising agrin, NRG1, ACh.

17. The method of claim 16, wherein the composition further comprises a collagen scaffold, optionally, wherein the collagen scaffold is a gelatin scaffold.

18. The method of claim 16, wherein muscle atrophy in the subject is attenuated.

19. The method of claim 16, wherein glottic function in the subject is restored.

20. The method of claim 16, wherein the concentration of agrin is about 50 NM to about 5000 nM in the composition.

21. The method of claim 16, wherein the concentration of NRG1 is about 0.1 nM to about 100 nM in the composition.

22. The method of claim 16. wherein the concentration of Ach is about 10 micromolar to about 1000 micromolar.

23. The method of claim 16, wherein the concentration of agrin is about 500 micromolar, the concentration of NRG is about 1 nM, and the concentration of ACh is about 100 micromolar.

24. The method of claim 16, wherein the composition is administered to the subject via injection, optionally injection into muscle.

25. The method of claim 16, wherein the composition is administered into the thyroarytenoid (TA) muscle.

26. The method of claim 16, wherein the composition is administered once to the subject.

27. The method of claim 16, wherein the composition is administered multiple times to the subj ect.

28. A pharmaceutical composition comprising agrin, neuregulin (NRG1), and acetylcholine (ACh).

29. The pharmaceutical composition of claim 28, further comprising a collagen scaffold, optionally, wherein the collagen scaffold is a gelatin scaffold.Atty Docket No. 144578.00484 30. The pharmaceutical composition of claim 28, wherein the concentration of agrin is about 1 nM to about 1000 mM in the composition.

31. The pharmaceutical composition of claim 28, wherein the concentration of NRG1 is about 0.1 nM to about 10 nM in the composition.

32. The pharmaceutical composition of claim 28, wherein the concentration of Ach is about 10 pM to about 1000 pM.

33. The pharmaceutical composition of claim 28, wherein the concentration of agrin is about 500 nM, the concentration of NRG is about 1 nM, and the concentration of ACh is about 100 M.

34. A method of treating recurrent lary ngeal nerve (RLN) injury' in a subject comprising administering a composition comprising agrin, neuregulin (NRG1). and acetylcholine (ACh) to the subject.

35. The method of claim 34, wherein the composition further comprises a collagen scaffold, optionally, wherein the collagen scaffold is a gelatin scaffold.

36. The method of claim 34, wherein the composition is administered to the subject via injection, optionally injection into muscle.

37. The method of claim 34, wherein muscle atrophy in the subject is attenuated.

38. The method of claim 34, wherein glottic function in the subject is restored.

39. The method of claim 34, wherein the concentration of agrin is about 50 nM to about 5000 nM in the composition.

40. The method of claim 34, wherein the concentration of NRG1 is about 0.1 nM to about 100 nM in the composition.

41. The method of claim 34, wherein the concentration of Ach is about 10 micromolar to about 1000 micromolar.

42. The method of claim 34, wherein the concentration of agrin is about 500 nM, the concentration of NRG is about 1 nM, and the concentration of ACh is about 100 micromolar.

43. The method of claim 34, wherein the composition is administered to the subject via injection, optionally injection into muscle.Atty Docket No. 144578.00484 44. The method of claim 34, wherein the composition is administered into the thyroarytenoid (TA) muscle.

45. The method of claim 34, wherein the composition is administered once to the subject.

46. The method of claim 34, wherein the composition is administered multiple times to the subject.